| 1 |
Zhang H, Xu Z, Gao H, Zhang Q. Systematic analysis on the mechanism of Zhizi-Bopi decoction against hepatitis B via network pharmacology and molecular docking. Biotechnol Lett 2023;45:463-78. [PMID: 36807721 DOI: 10.1007/s10529-023-03359-x] [Reference Citation Analysis]
|
| 2 |
Xiong Y, Xia Z, Yang L, Huang J. A novel nomogram to predict 90-day mortality in patients with hepatitis B virus-related acute-on-chronic liver failure: a single-center retrospective study. BMC Gastroenterol 2023;23:86. [PMID: 36964486 DOI: 10.1186/s12876-023-02727-1] [Reference Citation Analysis]
|
| 3 |
Pan Y, Xia H, He Y, Zeng S, Shen Z, Huang W. The progress of molecules and strategies for the treatment of HBV infection. Front Cell Infect Microbiol 2023;13. [DOI: 10.3389/fcimb.2023.1128807] [Reference Citation Analysis]
|
| 4 |
Papanastasatou M, Verykokakis M. Innate-like T lymphocytes in chronic liver disease. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1114605] [Reference Citation Analysis]
|
| 5 |
Kim DH, Choi Y, Jang J, Kim B. Global prevalence and molecular characteristics of three clades within hepatitis B virus subgenotype C2: Predominance of the C2(3) clade in South Korea. Front Microbiol 2023;14. [DOI: 10.3389/fmicb.2023.1137084] [Reference Citation Analysis]
|
| 6 |
Li S, Jin J, Jiang Y, Shi J, Jiang X, Lin N, Ma Z. Low levels of tenofovir in breast milk support breastfeeding in HBV-infected mothers treated with tenofovir disoproxil fumarate. Int J Antimicrob Agents 2023;61:106726. [PMID: 36646229 DOI: 10.1016/j.ijantimicag.2023.106726] [Reference Citation Analysis]
|
| 7 |
Gholizadeh O, Akbarzadeh S, Moein M, Yasamineh S, Hosseini P, Afkhami H, Amini P, Dadashpour M, Tahavvori A, Eslami M, Hossein Taherian M, Poortahmasebi V. The role of non-coding RNAs in the diagnosis of different stages (HCC, CHB, OBI) of hepatitis B infection. Microb Pathog 2023;176:105995. [PMID: 36681203 DOI: 10.1016/j.micpath.2023.105995] [Reference Citation Analysis]
|
| 8 |
Joseph NT, Banga J, Badell ML. An Overview of Antiviral Treatments in Pregnancy. Obstet Gynecol Clin North Am 2023;50:183-203. [PMID: 36822703 DOI: 10.1016/j.ogc.2022.10.017] [Reference Citation Analysis]
|
| 9 |
Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain. Aliment Pharmacol Ther 2023;57:540-8. [PMID: 36320189 DOI: 10.1111/apt.17280] [Reference Citation Analysis]
|
| 10 |
Zhang A, Yang F, Yuan Y, Li C, Huo X, Liu J, Zhou S, Li W, Zhang N, Liu J, Dong S, Fan H, Peng Y, Zheng J. OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro. Molecules 2023;28. [PMID: 36838982 DOI: 10.3390/molecules28041995] [Reference Citation Analysis]
|
| 11 |
Liblik K, Lam J, Pham A, Byun J, Farina JM, Baranchuk A. Sexually Transmitted Infections & the Heart. Curr Probl Cardiol 2023;48:101629. [PMID: 36740205 DOI: 10.1016/j.cpcardiol.2023.101629] [Reference Citation Analysis]
|
| 12 |
Liu Y, Wu Y, Jiang X, Chen B, Lu J, Cai Z, Fu B, Zheng W, Wu R, Chen G, Tian S, Ren J. Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection. iScience 2023;26:106100. [PMID: 36852272 DOI: 10.1016/j.isci.2023.106100] [Reference Citation Analysis]
|
| 13 |
Zhang Y, Han J, Zhang X, Li F, Guo Y, He J, Mao R, Zhu H, Yu J, Huang Y, Yang F, Zhang J. Lower frequency of MDSCs was significantly related to functional cure in CHB patients treated with peginterferon. Liver Int 2023;43:329-39. [PMID: 36453086 DOI: 10.1111/liv.15489] [Reference Citation Analysis]
|
| 14 |
O'Brien SF, Reedman CN, Osiowy C, Bolotin S, Yi QL, Lourenço L, Lewin A, Binka M, Caffrey N, Drews SJ. Hepatitis B Blood Donor Screening Data: An Under-Recognized Resource for Canadian Public Health Surveillance. Viruses 2023;15. [PMID: 36851623 DOI: 10.3390/v15020409] [Reference Citation Analysis]
|
| 15 |
Chen Q, Yan M, Lin H, Lai J, Yang Z, Hu D, Deng Y, Shi S, Shuai L, Zhang L, Zhang H, Bai L. Hepatocyte growth factor-mediated apoptosis mechanisms of cytotoxic CD8(+) T cells in normal and cirrhotic livers. Cell Death Discov 2023;9:13. [PMID: 36658107 DOI: 10.1038/s41420-023-01313-4] [Reference Citation Analysis]
|
| 16 |
Gao Z, Gao Z, Zhang H, Hou S, Zhou Y, Liu X. Targeting STING: From antiviral immunity to treat osteoporosis. Front Immunol 2022;13:1095577. [PMID: 36741390 DOI: 10.3389/fimmu.2022.1095577] [Reference Citation Analysis]
|
| 17 |
Shen C, Jiang X, Li M, Luo Y. Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers (Basel) 2023;15. [PMID: 36672482 DOI: 10.3390/cancers15020533] [Reference Citation Analysis]
|
| 18 |
Banerjee A, Athalye S, Khargekar N, Shingade P, Madkaikar M. Chronic Hepatitis B and Related Liver Diseases Are Associated with Reduced 25-Hydroxy-Vitamin D Levels: A Systematic Review and Meta-Analysis. Biomedicines 2023;11. [PMID: 36672644 DOI: 10.3390/biomedicines11010135] [Reference Citation Analysis]
|
| 19 |
Kikuchi K, Fukuda K, Hayashi S, Maeda T, Takashima Y, Fujita M, Ikuta K, Anjiki K, Tachibana S, Onoi Y, Matsumoto T, Kuroda R, Matsubara T. Polyarthritis presented in a patient with untreated chronic hepatitis B infection. Mod Rheumatol Case Rep 2023;7:320-3. [PMID: 36214605 DOI: 10.1093/mrcr/rxac075] [Reference Citation Analysis]
|
| 20 |
Demchenko AP. Fluorescent Light Opening New Horizons. Introduction to Fluorescence Sensing 2023. [DOI: 10.1007/978-3-031-19089-6_18] [Reference Citation Analysis]
|
| 21 |
Volinsky I. Mathematical Analysis of Hepatitis B Virus Combination Treatment. Springer Proceedings in Mathematics & Statistics 2023. [DOI: 10.1007/978-3-031-21484-4_22] [Reference Citation Analysis]
|
| 22 |
Dhara AK, Nayak AK. Introduction to antiviral therapy. Viral Infections and Antiviral Therapies 2023. [DOI: 10.1016/b978-0-323-91814-5.00025-8] [Reference Citation Analysis]
|
| 23 |
Squires KE, Ogilvie L, Jucov A, Anastasiy I, Ghicavii N, Huguet J, Melara R, Constantineau M, De La Rosa A, Mayers DL. A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection. J Viral Hepat 2023;30:19-28. [PMID: 36201354 DOI: 10.1111/jvh.13753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Xu C, Fan J, Liu D, Tuerdi A, Chen J, Wei Y, Pan Y, Dang H, Wei X, Yousif AS, Yogaratnam J, Zhou Q, Lichenstein H, Xu T. Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B. Hepatology 2023;77:275-89. [PMID: 35699669 DOI: 10.1002/hep.32614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 25 |
Shen Y, Wu SD, Chen Y, Li XY, Zhu Q, Nakayama K, Zhang WQ, Weng CZ, Zhang J, Wang HK, Wu J, Jiang W. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes 2023;15:2155018. [PMID: 36519342 DOI: 10.1080/19490976.2022.2155018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Chen YF, Wang Y, Wang Y, Luo YL, Lu ZD, Du XJ, Xu CF, Wang J. Optimized Cationic Lipid-assisted Nanoparticle for Delivering CpG Oligodeoxynucleotides to Treat Hepatitis B Virus Infection. Pharm Res 2023;40:145-56. [PMID: 36002611 DOI: 10.1007/s11095-022-03307-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 27 |
Feng G, Sun Y, Wang S, Lv Y, Yan C, Zhu Y, Zheng Y, Cui D. Phenotypes of peripheral CD4(+) T helper cell subsets in pregnant women with HBeAg-negative chronic asymptomatic HBV carriers. Front Cell Infect Microbiol 2023;13:1126311. [PMID: 36816578 DOI: 10.3389/fcimb.2023.1126311] [Reference Citation Analysis]
|
| 28 |
Chen X, Liu X, Jiang Y, Xia N, Liu C, Luo W. Abnormally primed CD8 T cells: The Achilles' heel of CHB. Front Immunol 2023;14:1106700. [PMID: 36936922 DOI: 10.3389/fimmu.2023.1106700] [Reference Citation Analysis]
|
| 29 |
Liu Z, Li Y, Wang Y, Bai X, Zhang Y. Exosomes in HBV infection. Clin Chim Acta 2023;538:65-9. [PMID: 36375524 DOI: 10.1016/j.cca.2022.11.012] [Reference Citation Analysis]
|
| 30 |
Giordano C, Picardi M, Pugliese N, Vincenzi A, Abagnale DP, De Fazio L, Giannattasio ML, Fatigati C, Ciriello M, Salemme A, Muccioli Casadei G, Vigliar E, Mascolo M, Troncone G, Pane F. Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21. Front Oncol 2023;13:1130899. [PMID: 36890828 DOI: 10.3389/fonc.2023.1130899] [Reference Citation Analysis]
|
| 31 |
Osawa Y, Ohtake T, Suto D, Akita T, Yamada H, Kohgo Y, Murata K. Cases of Rapid Hepatitis B Surface Antigen Reduction after COVID-19 Vaccination. Intern Med 2023;62:51-7. [PMID: 36261382 DOI: 10.2169/internalmedicine.0842-22] [Reference Citation Analysis]
|
| 32 |
He T, Ling N, Zhang G, Xiang D, Hu P, Peng M, Cai D, Zhang D, Chen M, Ren H. Decreased antibody response to influenza vaccine with an enhanced antibody response to subsequent SARS-CoV-2 vaccination in patients with chronic hepatitis B virus infection. Immun Inflamm Dis 2023;11:e759. [PMID: 36705404 DOI: 10.1002/iid3.759] [Reference Citation Analysis]
|
| 33 |
Jin X, Bi J. Prospects for NK-based immunotherapy of chronic HBV infection. Front Immunol 2022;13:1084109. [PMID: 36591230 DOI: 10.3389/fimmu.2022.1084109] [Reference Citation Analysis]
|
| 34 |
Qi T, Zhu C, Wang J, Li B, Huang Z, Zhu Z, Tu M, Deng G, Zheng X, Huang Y, Meng Z, Wang X, Qian Z, Li H, Gao Y, Liu F, Shang J, Shi Y, Lu X, Wang S, Li H, Chen J. MELD score < 18 rule out 28-day ACLF development among inpatients with hepatitis B-related previous compensated liver disease. J Viral Hepat 2022;29:1089-98. [PMID: 36081337 DOI: 10.1111/jvh.13747] [Reference Citation Analysis]
|
| 35 |
Zhao H, Yu Y, Wang Y, Zhao L, Yang A, Hu Y, Pan Z, Wang Z, Yang J, Han Q, Tian Z, Zhang J. Cholesterol accumulation on dendritic cells reverses chronic hepatitis B virus infection-induced dysfunction. Cell Mol Immunol 2022;19:1347-60. [PMID: 36369367 DOI: 10.1038/s41423-022-00939-1] [Reference Citation Analysis]
|
| 36 |
Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study. Hepatol Res 2022;52:975-84. [PMID: 35976670 DOI: 10.1111/hepr.13830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 37 |
Das S, Wang W, Ganesan M, Fonseca-Lanza F, Cobb DA, Bybee G, Sun Y, Guo L, Hanson B, Cohen SM, Gendelman HE, Osna NA, Edagwa BJ, Poluektova LY. An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression. Sci Adv 2022;8:eade9582. [PMID: 36563152 DOI: 10.1126/sciadv.ade9582] [Reference Citation Analysis]
|
| 38 |
Li Q, Sun B, Zhuo Y, Jiang Z, Li R, Lin C, Jin Y, Gao Y, Wang D. Interferon and interferon-stimulated genes in HBV treatment. Front Immunol 2022;13:1034968. [PMID: 36531993 DOI: 10.3389/fimmu.2022.1034968] [Reference Citation Analysis]
|
| 39 |
Wang W, Jia R, Song J, Zhang X, Zhou S, Wang F, Fu J. Immunogenicity of inactivated coronavirus disease 2019 vaccines in patients with chronic hepatitis B undergoing antiviral therapy. Front Microbiol 2022;13. [DOI: 10.3389/fmicb.2022.1056884] [Reference Citation Analysis]
|
| 40 |
You H, Ma L, Wang X, Zhang F, Han Y, Yao J, Pan X, Zheng K, Kong F, Tang R. The emerging role of DEAD/H-box helicases in hepatitis B virus infection. Front Cell Infect Microbiol 2022;12:1062553. [PMID: 36506030 DOI: 10.3389/fcimb.2022.1062553] [Reference Citation Analysis]
|
| 41 |
Liu LJ, Lv Z, Xue X, Xing ZY, Zhu F. Canonical WNT Signaling Activated by WNT7B Contributes to L-HBs-Mediated Sorafenib Resistance in Hepatocellular Carcinoma by Inhibiting Mitophagy. Cancers (Basel) 2022;14. [PMID: 36497264 DOI: 10.3390/cancers14235781] [Reference Citation Analysis]
|
| 42 |
Li J, Li J, Ji Q, Wang Z, Wang H, Zhang S, Fan S, Wang H, Kong D, Ren J, Zhou Y, Yang R, Zheng H. Nomogram based on spleen volume expansion rate predicts esophagogastric varices bleeding risk in patients with hepatitis B liver cirrhosis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.1019952] [Reference Citation Analysis]
|
| 43 |
Chen X, Zheng X, Wu H, Zhang B, Peng L, Xie C. Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review. Can J Gastroenterol Hepatol 2022;2022:7499492. [PMID: 36439633 DOI: 10.1155/2022/7499492] [Reference Citation Analysis]
|
| 44 |
Lian J, Kuang W, Jia H, Lu Y, Zhang X, Ye C, Gu J, Lv Y, Yu J, Zhang Y, Lu X, Zhao Y, Yang D, Wang K, Zhao P, Yu Y, Bai L, Zhang J, Zhang X, Yang Y. Pegylated interferon-α-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naïve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study. J Med Virol 2022;94:5475-83. [PMID: 35836102 DOI: 10.1002/jmv.28003] [Reference Citation Analysis]
|
| 45 |
Yang K, Pan Y, Zhang H, Jin L, Wang X. Hepatic vitamin D receptor expression is negatively associated with liver inflammation and fibrosis in patients with chronic HBV infection. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00919-9] [Reference Citation Analysis]
|
| 46 |
Zhong Y, Wu C, Xu Z, Teng Y, Zhao L, Zhao K, Wang J, Wang W, Zhan Q, Zhu C, Chen X, Liang K, Cheng X, Xia Y. Hepatitis B Virus Core Protein Is Not Required for Covalently Closed Circular DNA Transcriptional Regulation. J Virol 2022;:e0136222. [PMID: 36226986 DOI: 10.1128/jvi.01362-22] [Reference Citation Analysis]
|
| 47 |
Masset C, Le Turnier P, Bressollette-Bodin C, Renaudin K, Raffi F, Dantal J. Virus-Associated Nephropathies: A Narrative Review. Int J Mol Sci 2022;23:12014. [PMID: 36233315 DOI: 10.3390/ijms231912014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 48 |
Liu Y, Song N, Yao H, Jiang S, Wang Y, Zheng Y, Zhou Y, Ding J, Hu G, Lu M. β-Arrestin2-biased Drd2 agonist UNC9995 alleviates astrocyte inflammatory injury via interaction between β-arrestin2 and STAT3 in mouse model of depression. J Neuroinflammation 2022;19:240. [PMID: 36183107 DOI: 10.1186/s12974-022-02597-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 49 |
Gao N, Yu H, Zhang J, Mo Z, Chu J, Xie C, Peng L, Gao Z. Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy. J Viral Hepat 2022;29:899-907. [PMID: 35871534 DOI: 10.1111/jvh.13734] [Reference Citation Analysis]
|
| 50 |
Lian MJ, Chen ZQ, Wang QM, Zheng GS, Hong GL. Diagnostic accuracy of mac-2-binding protein glycosylation isomer for diagnosing hepatitis B-related fibrosis: A meta-analysis. J Dig Dis 2022;23:550-60. [PMID: 36251470 DOI: 10.1111/1751-2980.13140] [Reference Citation Analysis]
|
| 51 |
Akbar SMF, Mahtab MA, Khan S, Yoshida O, Hiasa Y. Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection. Vaccines (Basel) 2022;10. [PMID: 36298512 DOI: 10.3390/vaccines10101644] [Reference Citation Analysis]
|
| 52 |
Moskaliuk V, Rudan I. INVESTIGATIONS OF CHRONIC HEPATITIS B and C IN HIV-INFECTION. Med Sci of Ukr 2022;18:29-34. [DOI: 10.32345/2664-4738.3.2022.04] [Reference Citation Analysis]
|
| 53 |
Zang J, Liu M, Liu H, Ding L. A molecular simulation study of hepatitis B virus core protein and the nuclear protein allosteric modulators of phthalazinone derivatives. Phys Chem Chem Phys 2022. [PMID: 36129214 DOI: 10.1039/d2cp02946d] [Reference Citation Analysis]
|
| 54 |
Li G, Wang Z, Chen D, Yin J, Mo Z, Sun B, Yang T, Zhang X, Zhai Z, Li Y, Chen P, Dai Y, Wang Z, Ma J. Comprehensive analysis of a TPX2-related TRHDE-AS1/PKIA ceRNA network involving prognostic signatures in Hepatitis B virus-infected hepatocellular carcinoma. Front Cell Infect Microbiol 2022;12:1025900. [DOI: 10.3389/fcimb.2022.1025900] [Reference Citation Analysis]
|
| 55 |
Edinga BEE, Bigna JJ, Nansseu JR, Tchapmi AY, Mbouna SFM, Belinga S, Njoya O, Ama-Moor VJ, Njouom R. Simple noninvasive tests for liver fibrosis diagnosis in sub-Saharan African adults with chronic viral hepatitis B or C: A cross sectional study in Cameroon. Clin Chim Acta 2022;536:56-60. [PMID: 36155867 DOI: 10.1016/j.cca.2022.09.009] [Reference Citation Analysis]
|
| 56 |
Zhong S, Li Q, Wen C, Li Y, Zhou Y, Jin Z, Ye G, Zhao Y, Hou J, Li Y, Tang L. Interferon α facilitates anti-HBV cellular immune response in a B cell-dependent manner. Antiviral Res 2022;207:105420. [PMID: 36165866 DOI: 10.1016/j.antiviral.2022.105420] [Reference Citation Analysis]
|
| 57 |
Tony SM, Shaaban MEA, Mohamed AIM, Abdelrahim MEA. Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00294-0] [Reference Citation Analysis]
|
| 58 |
Feitelson MA, Arzumanyan A, Spector I, Medhat A. Hepatitis B x (HBx) as a Component of a Functional Cure for Chronic Hepatitis B. Biomedicines 2022;10:2210. [DOI: 10.3390/biomedicines10092210] [Reference Citation Analysis]
|
| 59 |
Cao G, Liu J, Liu M. Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study. Chin Med J (Engl) 2022;135:2049-55. [PMID: 36228164 DOI: 10.1097/CM9.0000000000002331] [Reference Citation Analysis]
|
| 60 |
Wang X, Gao X, Wu R, Chi X, Xu H, Guan Y, Jin Q, Niu J. Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients. J Gastroenterol Hepatol 2022;37:1806-14. [PMID: 35509262 DOI: 10.1111/jgh.15881] [Reference Citation Analysis]
|
| 61 |
Rao H, Shang J, Xie Q, Lian J, Gao P, Shi J, Chen X, Wang J, Xu M, Zhang L, Zhao Y, Mao Q, Wang M, Zhao W, Zhang Z, Jia J, Tang H, Zhang J, Zheng X, Liu C, Wei L. Tenofovir disoproxil fumarate therapy in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis. iLIVER 2022;1:145-153. [DOI: 10.1016/j.iliver.2022.08.006] [Reference Citation Analysis]
|
| 62 |
Liu YY, Lin CL, Weng CH, Chang PH, Chien CH, Huang KC, Hua MC, Hu CC. Older Age and High α-Fetoprotein Predict Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis-B-Related Cirrhotic Patients Receiving Long-Term Nucleos(t)ide Analogue Therapy. Diagnostics (Basel) 2022;12. [PMID: 36140487 DOI: 10.3390/diagnostics12092085] [Reference Citation Analysis]
|
| 63 |
Zhao JY, Zhong ZZ, Zhao LY, Li W. Key pathways and genes in hepatitis B virus-related liver inflammation: Expression profiling and bioinformatics analysis. Medicine (Baltimore) 2022;101:e30229. [PMID: 36042612 DOI: 10.1097/MD.0000000000030229] [Reference Citation Analysis]
|
| 64 |
Goto A, Rodriguez-Esteban R, Scharf SH, Morris GM. Understanding the genetics of viral drug resistance by integrating clinical data and mining of the scientific literature. Sci Rep 2022;12:14476. [PMID: 36008431 DOI: 10.1038/s41598-022-17746-3] [Reference Citation Analysis]
|
| 65 |
Bai L, Chen Q, Yan M, Lin H, Lai J, Yang Z, Hu D, Deng Y, Shi S, Shuai L, Zhang L, Zhang H. Hepatocyte growth factor-mediated apoptosis mechanisms of cytotoxic CD8+ T cells in normal and cirrhotic liver.. [DOI: 10.21203/rs.3.rs-1922450/v1] [Reference Citation Analysis]
|
| 66 |
Kim JH, Kim JH, Choe WH, Kwon SY, Yoo BC, Yoon EL, Kang SH. Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers. Antimicrob Agents Chemother 2022;66:e0027522. [PMID: 35867571 DOI: 10.1128/aac.00275-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 67 |
Volinsky I. Mathematical Model of Hepatitis B Virus Treatment with Support of Immune System. Mathematics 2022;10:2821. [DOI: 10.3390/math10152821] [Reference Citation Analysis]
|
| 68 |
Lian Y, Fu H, Xu X, Ju C. Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-7. [DOI: 10.1155/2022/9371497] [Reference Citation Analysis]
|
| 69 |
Saputro AH, Artarini AA, Tjahjono DH, Damayanti S. The long and stumble way to find potential active compounds from plants for defeating hepatitis B and C: review. PHAR 2022;69:699-708. [DOI: 10.3897/pharmacia.69.e85160] [Reference Citation Analysis]
|
| 70 |
Limdi JK. Editorial commentary on the Indian Journal of Gastroenterology-July-August 2022. Indian J Gastroenterol 2022;41:321-4. [PMID: 36087212 DOI: 10.1007/s12664-022-01293-w] [Reference Citation Analysis]
|
| 71 |
Lau FF, Bollerup S, Engsig F, Krarup H, Mygind LH, Hansen JB, Madsen LG, Thielsen P, Balslev U, Nielsen LN, Barfod TS, Clausen MR, Hobolth L, Laursen AL, Tarp B, Roege BT, Gerstoft J, Christensen PB, Weis N. Ischemic Heart Disease in Chronic Hepatitis B: A Danish Nationwide Cohort Study. Clin Epidemiol 2022;14:879-88. [PMID: 35879942 DOI: 10.2147/CLEP.S361910] [Reference Citation Analysis]
|
| 72 |
Chu JYK, Chuang YC, Tsai KN, Pantuso J, Ishida Y, Saito T, Ou JJ. Autophagic membranes participate in hepatitis B virus nucleocapsid assembly, precore and core protein trafficking, and viral release. Proc Natl Acad Sci U S A 2022;119:e2201927119. [PMID: 35858426 DOI: 10.1073/pnas.2201927119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 73 |
Zhou X, Matskova L, Zheng S, Wang X, Wang Y, Xiao X, Mo Y, Wölke M, Li L, Zheng Q, Huang G, Zhang Z, Ernberg I. Mechanisms of Anergic Inflammatory Response in Nasopharyngeal Carcinoma Cells Despite Ubiquitous Constitutive NF-κB Activation. Front Cell Dev Biol 2022;10:861916. [DOI: 10.3389/fcell.2022.861916] [Reference Citation Analysis]
|
| 74 |
Kanzaki H, Chiba T, Kaneko T, Ao J, Kan M, Muroyama R, Nakamoto S, Kanda T, Maruyama H, Kato J, Zen Y, Kotani A, Sekiba K, Otsuka M, Ohtsuka M, Kato N. The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells. Int J Mol Sci 2022;23:7878. [PMID: 35887229 DOI: 10.3390/ijms23147878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 75 |
Choi YR, Chen MC, Carrai M, Rizzo F, Chai Y, Tse M, Jackson K, Martella V, Steiner J, Pesavento PA, Beatty JA, Barrs VR. Hepadnavirus DNA Is Detected in Canine Blood Samples in Hong Kong but Not in Liver Biopsies of Chronic Hepatitis or Hepatocellular Carcinoma. Viruses 2022;14:1543. [PMID: 35891523 DOI: 10.3390/v14071543] [Reference Citation Analysis]
|
| 76 |
Zhang H, Xian J, Li Y, Xiao L, Wang L. Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med 2022;2022:1889628. [PMID: 35815265 DOI: 10.1155/2022/1889628] [Reference Citation Analysis]
|
| 77 |
Shirai K, Hikita H, Sakane S, Narumi R, Adachi J, Doi A, Tanaka S, Tahata Y, Yamada R, Kodama T, Sakamori R, Tatsumi T, Mita E, Tomonaga T, Takehara T. Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients. PLoS ONE 2022;17:e0271020. [DOI: 10.1371/journal.pone.0271020] [Reference Citation Analysis]
|
| 78 |
Chen B, Chen Y, Li J, Wang C, Song W, Wen Y, Lin J, Wu Y, Ying T, Zheng C. A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. mBio. [DOI: 10.1128/mbio.01612-22] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 79 |
Bhat SA, Kazim SN. HBV cccDNA─A Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure. ACS Omega. [DOI: 10.1021/acsomega.2c02216] [Reference Citation Analysis]
|
| 80 |
Shiue SJ, Cheng CL, Shiue HS, Chen CN, Cheng SW, Wu LW, Jargalsaikhan G, Chan TS, Lin HY, Wu MS. Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile. Nutrients 2022;14:2790. [PMID: 35889747 DOI: 10.3390/nu14142790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 81 |
Xiong Y, Xia Z, Yang L, Huang J. Low T3 syndrome is associated with poor prognosis in patients with hepatitis B virus-related acute-on-chronic liver failure. Expert Rev Gastroenterol Hepatol 2022;16:681-7. [PMID: 35723536 DOI: 10.1080/17474124.2022.2090336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 82 |
Chun HS, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. Dig Dis Sci 2022;67:3412-25. [PMID: 34476661 DOI: 10.1007/s10620-021-07157-1] [Reference Citation Analysis]
|
| 83 |
Lin C, Huang Y, Luo L, Fang F, Zhang J, Xun Z, Fu Y, Shang H, Liu C, Ou Q. Adenosine Triphosphate in Serum as a Promising Biomarker for Differential Diagnosis of Hepatitis B Disease Progression. Front Immunol 2022;13:927761. [DOI: 10.3389/fimmu.2022.927761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 84 |
Sun J, Yu X, Weng Z, Jin L, Yang J, Zhang H, Gu J, Wang N, Yang J. The impact of hepatotoxic drugs on the outcome of patients with acute deterioration of hepatitis B virus-related chronic disease. Eur J Gastroenterol Hepatol 2022;34:782-90. [PMID: 35506899 DOI: 10.1097/MEG.0000000000002365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 85 |
Yun B, Ahn SH, Yoon JH, Kim BK. Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study. Hepatol Commun 2022. [PMID: 35766457 DOI: 10.1002/hep4.2022] [Reference Citation Analysis]
|
| 86 |
Korbecki J, Szatkowska I, Kupnicka P, Żwierełło W, Barczak K, Poziomkowska-gęsicka I, Wójcik J, Chlubek D, Baranowska-bosiacka I. The Importance of CXCL1 in the Physiological State and in Noncancer Diseases of the Oral Cavity and Abdominal Organs. IJMS 2022;23:7151. [DOI: 10.3390/ijms23137151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 87 |
Popa GL, Popa MI. Oxidative Stress in Chronic Hepatitis B—An Update. Microorganisms 2022;10:1265. [DOI: 10.3390/microorganisms10071265] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 88 |
Song Z, Ma Y, Jiang D, Zhao R, Dong F. Long-Term Safety of Rituximab in DLBCL Patients With Hepatitis B-Related Cirrhosis: A Retrospective Case Series. Front Med (Lausanne) 2022;9:890339. [PMID: 35712098 DOI: 10.3389/fmed.2022.890339] [Reference Citation Analysis]
|
| 89 |
Shamaa O, Mendiratta V, Trudeau S, Gordon SC. Evolving Screening and Vaccination Recommendations for Hepatitis B in the USA. Curr Hepatology Rep 2022;21:37-43. [DOI: 10.1007/s11901-022-00583-3] [Reference Citation Analysis]
|
| 90 |
Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]
|
| 91 |
Sheng X, Zhou J, Gu X, Wang H, Li C. The Effect of Artificial Liver Support System on Prognosis of HBV-Derived Hepatorenal Syndrome: A Retrospective Cohort Study. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/3451544] [Reference Citation Analysis]
|
| 92 |
Zhao LN, Yuan HF, Wang YF, Yun HL, Zheng W, Yuan Y, Geng Y, Zhao M, Feng LY, Zhang XD. IFN-α inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver. Acta Pharmacol Sin 2022;43:1484-94. [PMID: 34497374 DOI: 10.1038/s41401-021-00765-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 93 |
Maamor NH, Muhamad NA, Mohd Dali NS, Abdul Mutalip MH, Leman FN, Aris T, Lai NM, Abu Hassan MR. Seroprevalence of Hepatitis B Among Healthcare Workers in Asia and Africa and Its Association With Their Knowledge and Awareness: A Systematic Review and Meta-Analysis. Front Public Health 2022;10:859350. [PMID: 35570890 DOI: 10.3389/fpubh.2022.859350] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 94 |
Zhang C, Zhang C. Analysis of current status of quantitative detection of biomarkers for liver fibrosis in Clinical labs in China. J Clin Lab Anal 2022;:e24490. [PMID: 35587485 DOI: 10.1002/jcla.24490] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 95 |
Cui D, Jiang D, Yan C, Liu X, Lv Y, Xie J, Chen Y. Immune Checkpoint Molecules Expressed on CD4+ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative. Front Microbiol 2022;13:887408. [PMID: 35572697 DOI: 10.3389/fmicb.2022.887408] [Reference Citation Analysis]
|
| 96 |
Nanwa N, Kwong JC, Feld JJ, Fangyun Wu C, Sander B. The mean attributable health care costs associated with hepatitis B virus in Ontario, Canada: A matched cohort study. CanLivJ. [DOI: 10.3138/canlivj-2021-0029] [Reference Citation Analysis]
|
| 97 |
Li J, Yu M, Zong R, Fan C, Ren F, Wu W, Li C. Deacetylation of Notch1 by SIRT1 contributes to HBsAg- and HBeAg-mediated M2 macrophage polarization. Am J Physiol Gastrointest Liver Physiol 2022;322:G459-71. [PMID: 35234049 DOI: 10.1152/ajpgi.00338.2021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 98 |
Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 99 |
Lan W, Wang Y, Zhou Z, Sun X, Zhang Y, Zhang F. Metabolic Regulation of Hepatitis B Virus Infection in HBV-Transgenic Mice. Metabolites 2022;12:287. [DOI: 10.3390/metabo12040287] [Reference Citation Analysis]
|
| 100 |
Malik GF, Zakaria N, Majeed MI, Ismail FW. Viral Hepatitis - The Road Traveled and the Journey Remaining. Hepat Med 2022;14:13-26. [PMID: 35300491 DOI: 10.2147/HMER.S352568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 101 |
Rong G, Chen Y, Yu Z, Li Q, Bi J, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chen Y, Dong Z, Bai W, Yoshida EM, Mendez-Sanchez N, Hu KQ, Qi X, Yang Y. Synergistic Effect of Biejia-Ruangan on Fibrosis Regression in Patients With Chronic Hepatitis B Treated With Entecavir: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Infect Dis 2022;225:1091-9. [PMID: 32437567 DOI: 10.1093/infdis/jiaa266] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 102 |
Zhao HJ, Hu YF, Han QJ, Zhang J. Innate and adaptive immune escape mechanisms of hepatitis B virus. World J Gastroenterol 2022; 28(9): 881-896 [DOI: 10.3748/wjg.v28.i9.881] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 103 |
Albuquerque-Souza E, Sahingur SE. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis. Periodontol 2000 2022. [PMID: 35244954 DOI: 10.1111/prd.12427] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 104 |
Masetti C, Pugliese N, Aghemo A, Viganò M. Safety of current antiviral drugs for chronic hepatitis B. Expert Opin Drug Saf 2022. [PMID: 35209776 DOI: 10.1080/14740338.2022.2045271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 105 |
Jiang S, Wang X, Chen K, Yang P. Establishment of an inducible cell line for Hepatitis B virus genotype C2 and its pharmacological responses to interferons. Pharmacol Res 2022;:106142. [PMID: 35218895 DOI: 10.1016/j.phrs.2022.106142] [Reference Citation Analysis]
|
| 106 |
Song HF, Chen XJ, Tang PJ, Xu P, Huang ZY, Wang XF. Clinical Significance of BTLA and HVEM Expression on Circulating CD4+ T and CD8+ T Cells in Chronic Hepatitis B Virus Infection. Viral Immunol 2022. [PMID: 35196150 DOI: 10.1089/vim.2021.0134] [Reference Citation Analysis]
|
| 107 |
Anwer A, Khan S, Amir F, Bhat SA, Azam SA, Hasan SK, Afroz M, Waseem R, Islam A, Parveen S, Kazim SN. Novel chimeric vectors harboring hepatitis B viral promoter and reporter gene demonstrated liver-specific significance. Future Virology. [DOI: 10.2217/fvl-2021-0259] [Reference Citation Analysis]
|
| 108 |
Barré T, Fontaine H, Pol S, Ramier C, Di Beo V, Protopopescu C, Marcellin F, Bureau M, Bourlière M, Dorival C, Petrov-sanchez V, Asselah T, Delarocque-astagneau E, Larrey D, Duclos-vallée J, Carrat F, Carrieri P; on behalf of the ANRS/AFEF Hepather Study Group. Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort). Antioxidants 2022;11:379. [DOI: 10.3390/antiox11020379] [Reference Citation Analysis]
|
| 109 |
Huang Y, Zheng S, Guo Z, de Mollerat du Jeu X, Liang XJ, Yang Z, Zhang HY, Gao S, Liang Z. Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B. Signal Transduct Target Ther 2022;7:38. [PMID: 35145057 DOI: 10.1038/s41392-021-00859-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 110 |
Parvez MK, Al-dosari MS, Tabish Rehman M, Al-rehaily AJ, Alqahtani A, Alajmi MF. The anti-hepatitis B virus and anti-hepatotoxic efficacies of solanopubamine, a rare alkaloid from Solanum schimperianum. Saudi Pharmaceutical Journal 2022. [DOI: 10.1016/j.jsps.2022.02.001] [Reference Citation Analysis]
|
| 111 |
Wang Y, Mei Y, Ao Z, Chen Y, Jiang Y, Chen X, Qi R, Fu B, Tang J, Fang M, You M, Zhang T, Yuan Q, Luo W, Xia N. A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 112 |
Jiang K, Zhang L, Li J, Hu H, Huang Q, Qiu T, Mo X, Ren J, Guo W, Tao Y, Cui H, Zuo Y, Chen X, Xie Y, Li Y, Liang H, Liu Z, Xie L, Mao R, Jiang Q, Huang K. Diagnostic efficacy of FibroScan for liver inflammation in patients with chronic hepatitis B: a single-center study with 1185 liver biopsies as controls. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02108-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 113 |
Tricot T, Thibaut HJ, Abbasi K, Boon R, Helsen N, Kumar M, Neyts J, Verfaillie C. Metabolically Improved Stem Cell Derived Hepatocyte-Like Cells Support HBV Life Cycle and Are a Promising Tool for HBV Studies and Antiviral Drug Screenings. Biomedicines 2022;10:268. [DOI: 10.3390/biomedicines10020268] [Reference Citation Analysis]
|
| 114 |
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10295-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 115 |
Qin Y, Yu H, Yuan S, Yang Z, Ren F, Wang Q, Li F, Ren J, Cheng S, Zhou Y, He X, Zhou H, Zhang Y, Tan M, Yang M, Zhang D, Wen X, Dong M, Zhang H, Liu J, Li Z, Chen Y, Huang A, Chen W, Chen J. KAT2A Promotes Hepatitis B Virus Transcription and Replication Through Epigenetic Regulation of cccDNA Minichromosome. Front Microbiol 2022;12:795388. [DOI: 10.3389/fmicb.2021.795388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 116 |
Dondeti MF, Abdelkhalek MS, El-din Elezawy HM, Alsanie WF, Raafat BM, Gamal-eldeen AM, Talaat RM. Association between interferon-gamma (IFN-γ) gene polymorphisms (+874A/T and +2109A/G), and susceptibility to hepatitis B viral infection (HBV). J Appl Biomed. [DOI: 10.32725/jab.2022.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 117 |
Wei L, Zhao T, Zhang J, Mao Q, Gong G, Sun Y, Chen Y, Wang M, Tan D, Gong Z, Li B, Niu J, Li S, Gong H, Zou L, Zhou W, Jia Z, Tang Y, Fei L, Hu Y, Shang X, Han J, Zhang B, Wu Y. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial. Hepatology 2022;75:182-95. [PMID: 34396571 DOI: 10.1002/hep.32109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 118 |
Ong XRS, Bagguley D, Lawrentschuk N, Johnson D. Sexually Transmitted Diseases. Men’s Health and Wellbeing 2022. [DOI: 10.1007/978-3-030-84752-4_10] [Reference Citation Analysis]
|
| 119 |
Zhao W, Liu X. MiR-3682 promotes the progression of hepatocellular carcinoma (HCC) via inactivating AMPK signaling by targeting ADRA1A. Ann Hepatol 2022;27 Suppl 1:100570. [PMID: 34706275 DOI: 10.1016/j.aohep.2021.100570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 120 |
Gish RG, Asselah T, Squires K, Mayers D. Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens. Antivir Chem Chemother 2022;30:204020662211387. [DOI: 10.1177/20402066221138705] [Reference Citation Analysis]
|
| 121 |
Kim S, Yoo S, Lee JI, Kim S, Chang HY, Kim D, Jeong SH, Lee KS, Lee HW. Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance. Dig Dis Sci 2022;67:321-8. [PMID: 33517556 DOI: 10.1007/s10620-021-06845-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 122 |
Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 2022;22:19-32. [PMID: 34002067 DOI: 10.1038/s41577-021-00549-4] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 93.0] [Reference Citation Analysis]
|
| 123 |
Seong G, Sinn DH, Kang W, Gwak GY, Choi MS, Lee JH, Koh KC, Woon Paik S, Paik YH. Age and fibrosis index for the prediction of hepatocellular carcinoma risk in patients with high hepatitis B virus DNA but normal alanine aminotransferase. Eur J Gastroenterol Hepatol 2022;34:69-75. [PMID: 32925504 DOI: 10.1097/MEG.0000000000001915] [Reference Citation Analysis]
|
| 124 |
Chen XF, Zhao X, Yang Z. Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases. J Med Chem 2021;64:17601-26. [PMID: 34854680 DOI: 10.1021/acs.jmedchem.1c01567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 125 |
Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 126 |
Tang Y, Wang C, Fu S, Li T, He G. Intrahepatic Biliary Cystadenoma With Colonic Adenomatous Polyps in a Patient With Chronic Hepatitis B: A Case Report and Literature Review. Front Med 2021;8. [DOI: 10.3389/fmed.2021.760607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 127 |
Wu LL, Li XY, Deng H, Xie DY, Gu YR, Bi YH, Huang YH, Gao ZL. Transforming growth factor-β: An early predictor of a functional cure in chronic hepatitis B treated with interferon. Virus Res 2021;309:198657. [PMID: 34919970 DOI: 10.1016/j.virusres.2021.198657] [Reference Citation Analysis]
|
| 128 |
Wang J, Du L, Tang H. Suppression of Interferon-α Treatment Response by Host Negative Factors in Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:784172. [PMID: 34901094 DOI: 10.3389/fmed.2021.784172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 129 |
Li J, Chen H, Chen J, Zhou B, Hou J, Jiang DK. A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B. Pharmgenomics Pers Med 2021;14:1505-15. [PMID: 34848996 DOI: 10.2147/PGPM.S337962] [Reference Citation Analysis]
|
| 130 |
Sherif DA, Makled MN, Suddek GM. The HIV reverse transcriptase Inhibitor Tenofovir suppressed DMH/HFD-induced colorectal cancer in Wistar rats. Fundam Clin Pharmacol 2021;35:940-54. [PMID: 33829539 DOI: 10.1111/fcp.12679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 131 |
Su PY, Su WW, Hsu YC, Huang SP, Yen HH. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. PeerJ 2021;9:e12527. [PMID: 34820208 DOI: 10.7717/peerj.12527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 132 |
Tarn WY, Cheng Y, Ko SH, Huang LM. Antisense Oligonucleotide-Based Therapy of Viral Infections. Pharmaceutics 2021;13:2015. [PMID: 34959297 DOI: 10.3390/pharmaceutics13122015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 133 |
Lu CM, Cheng JS, Sun WC, Chen WC, Tsay FW, Wang HM, Tsai TJ, Kao SS, Li YD, Li YR, Lin HS, Yin CH, Tsai WL. Tenofovir versus lamivudine followed by tenofovir in severe exacerbation of hepatitis B: a randomized controlled study. Antimicrob Agents Chemother 2021;:AAC0166421. [PMID: 34807763 DOI: 10.1128/AAC.01664-21] [Reference Citation Analysis]
|
| 134 |
Niño-Sandoval TC, Rocha NS, Sarinho FW, Vasconcelos CFM, Vasconcelos AFM, Vasconcelos BC. Effect of autohemotherapy in the treatment of viral infections - a systematic review. Public Health 2021;201:78-88. [PMID: 34798327 DOI: 10.1016/j.puhe.2021.09.024] [Reference Citation Analysis]
|
| 135 |
Fan J, Fu JL, Wang FS. Boosting viral-specific immunotherapy for chronic hepatitis B treatment. Cell Mol Immunol 2021;18:2586-7. [PMID: 34782758 DOI: 10.1038/s41423-021-00788-4] [Reference Citation Analysis]
|
| 136 |
Jin X, Yan ZH, Lu L, Lu S, Zhang G, Lin W. Peripheral Immune Cells Exhaustion and Functional Impairment in Patients With Chronic Hepatitis B. Front Med (Lausanne) 2021;8:759292. [PMID: 34782855 DOI: 10.3389/fmed.2021.759292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 137 |
Alqahtani SA, Colombo M. Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma. Cells 2021;10:3091. [PMID: 34831314 DOI: 10.3390/cells10113091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 138 |
Zhu B, Lv X, Zhao Z, Chen L, Chen X, Li C, Li S, Dai E. Comparison of the efficacy and safety of tenofovir and telbivudine in interrupting mother-to-child transmission of hepatitis B virus. Medicine (Baltimore) 2021;100:e27695. [PMID: 34871254 DOI: 10.1097/MD.0000000000027695] [Reference Citation Analysis]
|
| 139 |
Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 140 |
Song J, Ou G, Lai X, Tian X, Wang L, Zhang K, Wang L, Zhang X, Zhao C, Zhuang H, Xiang K, Li T. The enhancement role of Matrigel on HBV infection in HepG2-NTCP cells. J Virol Methods 2022;299:114345. [PMID: 34728272 DOI: 10.1016/j.jviromet.2021.114345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 141 |
Goto A, Rodriguez-esteban R, Scharf SH, Morris GM. Understanding the Genetics of Viral Drug Resistance by Integrating Clinical Data and Mining of the Scientific Literature.. [DOI: 10.1101/2021.10.26.465417] [Reference Citation Analysis]
|
| 142 |
Zhang C, Li JW, Wu Z, Zhao H, Wang GQ. Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis. J Clin Transl Hepatol 2021;9:615-25. [PMID: 34722176 DOI: 10.14218/JCTH.2020.00136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 143 |
Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 144 |
Ma Y, Yang L, Bao Y, Yang Y, Chen L, Zheng M. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy. Front Immunol 2021;12:751754. [PMID: 34691067 DOI: 10.3389/fimmu.2021.751754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 145 |
Zhu S, Wu L, Mei Y, Liu Z, Lin L, Yuan J, Li J, Li X, Peng L. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol. BMJ Open 2021;11:e049104. [PMID: 34697111 DOI: 10.1136/bmjopen-2021-049104] [Reference Citation Analysis]
|
| 146 |
Cui D, Li W, Jiang D, Wu J, Xie J, Wu Y. Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. Front Med (Lausanne) 2021;8:754709. [PMID: 34660653 DOI: 10.3389/fmed.2021.754709] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 147 |
Gao P, Luo Y, Chen L, Yang Z, He Q, Li J. The effect of hepatitis B virus on T lymphocyte and its subsets in chronic hepatitis B patients in different ALT stages: A new concept ALT in HBV infection. Int Immunopharmacol 2021;101:108182. [PMID: 34601330 DOI: 10.1016/j.intimp.2021.108182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 148 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
|
| 149 |
Na JE, Sinn DH, Lee JH, Jang HJ, Baek SY, Kim KA, Kang WS, Gwak GY, Paik YH, Kim YJ, Choi MS, Yoon JH, Lee JH, Koh KC, Paik SW. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat 2021;28:1392-9. [PMID: 34251707 DOI: 10.1111/jvh.13572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 150 |
Asín-Prieto E, Parra-Guillen ZP, Gómez Mantilla JD, Vandenbossche J, Stuyckens K, de Trixhe XW, Perez-Ruixo JJ, Troconiz IF. A quantitative systems pharmacology model for acute viral hepatitis B. Comput Struct Biotechnol J 2021;19:4997-5007. [PMID: 34589180 DOI: 10.1016/j.csbj.2021.08.052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 151 |
Wang X, Wei Z, Jiang Y, Meng Z, Lu M. mTOR Signaling: The Interface Linking Cellular Metabolism and Hepatitis B Virus Replication. Virol Sin 2021. [PMID: 34580816 DOI: 10.1007/s12250-021-00450-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 152 |
Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 153 |
Lee HW, Yip TC, Tse YK, Wong GL, Kim BK, Kim SU, Park JY, Kim DY, Chan HL, Ahn SH, Wong VW. Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. Clin Gastroenterol Hepatol 2021;19:1950-1958.e7. [PMID: 32889148 DOI: 10.1016/j.cgh.2020.08.064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 154 |
Koshiol J, Argirion I, Liu Z, Kim Lam T, O'Brien TR, Yu K, McGlynn KA, Petrick JL, Pinto L, Chen CJ, Hildesheim A, Pfeiffer RM, Lee MH, Yang HI. Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals. Aliment Pharmacol Ther 2021;54:833-42. [PMID: 34286851 DOI: 10.1111/apt.16524] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 155 |
Zhao F, Xie X, Tan X, Yu H, Tian M, Lv H, Qin C, Qi J, Zhu Q. The Functions of Hepatitis B Virus Encoding Proteins: Viral Persistence and Liver Pathogenesis. Front Immunol 2021;12:691766. [PMID: 34456908 DOI: 10.3389/fimmu.2021.691766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 156 |
Xue R, Yang J, Wu J, Wang Z, Meng Q. Novel Prognostic Models for Predicting the 180-day Outcome for Patients with Hepatitis-B Virus-related Acute-on-chronic Liver Failure. J Clin Transl Hepatol 2021;9:514-20. [PMID: 34447680 DOI: 10.14218/JCTH.2021.00028] [Reference Citation Analysis]
|
| 157 |
Zhang T, Zhang G, Deng X, Zeng J, Jin J, Zeping H, Wu M, Zheng R. APS (Age, Platelets, 2D Shear-Wave Elastography) Score Predicts Hepatocellular Carcinoma in Chronic Hepatitis B. Radiology 2021;301:350-9. [PMID: 34427463 DOI: 10.1148/radiol.2021204700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 158 |
Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
|
| 159 |
Volinsky I. Stability Analysis of a Mathematical Model of Hepatitis B Virus with Unbounded Memory Control on the Immune System in the Neighborhood of the Equilibrium Free Point. Symmetry 2021;13:1437. [DOI: 10.3390/sym13081437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 160 |
Khalili M, Kleiner DE, King WC, Sterling RK, Ghany MG, Chung RT, Bhan AK, Rosenthal P, Lisker-Melman M, Ramachandran R, Lok AS; ; and the Hepatitis B Research Network (HBRN). Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. Am J Gastroenterol 2021;116:1686-97. [PMID: 33840726 DOI: 10.14309/ajg.0000000000001257] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 161 |
Le C, Liu Y, López-Orozco J, Joyce MA, Le XC, Tyrrell DL. CRISPR Technique Incorporated with Single-Cell RNA Sequencing for Studying Hepatitis B Infection. Anal Chem 2021;93:10756-61. [PMID: 34328316 DOI: 10.1021/acs.analchem.1c02227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 162 |
Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 163 |
Li J, Hu CH, Chen Y, Zhou MM, Gao ZJ, Fu MJ, Wang J, Li JZ, Chen TY, Zhao YR, He YL. Characteristics of Peripheral Lymphocyte Subsets in Patients With Acute-On-Chronic Liver Failure Associated With Hepatitis B. Front Med (Lausanne) 2021;8:689865. [PMID: 34386507 DOI: 10.3389/fmed.2021.689865] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 164 |
Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 165 |
Zhao H, Wang H, Hu Y, Xu D, Yin C, Han Q, Zhang J. Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV. Int J Nanomedicine 2021;16:4913-28. [PMID: 34321879 DOI: 10.2147/IJN.S317113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 166 |
Kok F, Rosenblatt M, Teusel M, Nizharadze T, Gonçalves Magalhães V, Dächert C, Maiwald T, Vlasov A, Wäsch M, Tyufekchieva S, Hoffmann K, Damm G, Seehofer D, Boettler T, Binder M, Timmer J, Schilling M, Klingmüller U. Disentangling molecular mechanisms regulating sensitization of interferon alpha signal transduction. Mol Syst Biol 2020;16:e8955. [PMID: 32696599 DOI: 10.15252/msb.20198955] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
|
| 167 |
Ma Z, Li S, He D, Wang Y, Jiang H, Zhou H, Jin J, Lin N. Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2020;34:e8728. [PMID: 31960519 DOI: 10.1002/rcm.8728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 168 |
Yu HB, Cheng ST, Ren F, Chen Y, Shi XF, Wong VKW, Law BYK, Ren JH, Zhong S, Chen WX, Xu HM, Zhang ZZ, Hu JL, Cai XF, Hu Y, Zhang WL, Long QX, He L, Hu ZW, Jiang H, Zhou HZ, Huang AL, Chen J. SIRT7 restricts HBV transcription and replication through catalyzing desuccinylation of histone H3 associated with cccDNA minichromosome. Clin Sci (Lond) 2021;135:1505-22. [PMID: 34128977 DOI: 10.1042/CS20210392] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 169 |
Gailhouste L, Sudoh M, Qin XY, Watashi K, Wakita T, Ochiya T, Matsuura T, Kojima S, Furutani Y. Epigenetic reprogramming promotes the antiviral action of IFNα in HBV-infected cells. Cell Death Discov 2021;7:130. [PMID: 34078875 DOI: 10.1038/s41420-021-00515-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 170 |
Guo X, Sun M, Gao R, Qu A, Chen C, Xu C, Kuang H, Xu L. Ultrasmall Copper (I) Sulfide Nanoparticles Prevent Hepatitis B Virus Infection. Angew Chem Int Ed Engl 2021;60:13073-80. [PMID: 33837622 DOI: 10.1002/anie.202103717] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 171 |
Guo X, Sun M, Gao R, Qu A, Chen C, Xu C, Kuang H, Xu L. Ultrasmall Copper (I) Sulfide Nanoparticles Prevent Hepatitis B Virus Infection. Angew Chem 2021;133:13183-13190. [DOI: 10.1002/ange.202103717] [Reference Citation Analysis]
|
| 172 |
Khanam A, Chua JV, Kottilil S. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. Int J Mol Sci 2021;22:5497. [PMID: 34071064 DOI: 10.3390/ijms22115497] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
|
| 173 |
Cohen JM, Kridin K, Perez-Chada LM, Merola JF, Cohen AD. Hepatitis B and C among patients with hidradenitis suppurativa: a population-based study. Int J Dermatol 2021. [PMID: 33998670 DOI: 10.1111/ijd.15578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 174 |
Yang JM, Chen LP, Wang YJ, Lyu B, Zhao H, Shang ZY, Li J, Fan ZY, Wu SD, Ming X, Li X, Huang SP, Cheng JL. Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial. Chin Med J (Engl) 2020;133:1639-48. [PMID: 32568867 DOI: 10.1097/CM9.0000000000000857] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 175 |
Bekçibaşı M, Deveci Ö, Oğuz A, Bozkurt F, Dayan S, Çelen MK. Serum TNF-α, IL-1β, and IL-6 levels in chronic HBV-infected patients. Int J Clin Pract 2021;75:e14292. [PMID: 33930244 DOI: 10.1111/ijcp.14292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 176 |
Bidram E, Esmaeili Y, Amini A, Sartorius R, Tay FR, Shariati L, Makvandi P. Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside. ACS Biomater Sci Eng 2021;7:2150-76. [PMID: 33979143 DOI: 10.1021/acsbiomaterials.1c00318] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 177 |
Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection. Pharmaceuticals (Basel) 2021;14:454. [PMID: 34064831 DOI: 10.3390/ph14050454] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 178 |
Chen S, Li H, Lin X, Hu S, Zhang Z. Development and Evaluation of Nutrition Screening Tool in Patients with Hepatitis B-Related Cirrhosis: A Cross-Sectional Study. Risk Manag Healthc Policy 2021;14:1823-31. [PMID: 33986619 DOI: 10.2147/RMHP.S299428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 179 |
Li L, Ye Y, Ran Y, Liu S, Tang Q, Liu Y, Liao X, Zhang J, Xiao G, Lu J, Zhang G, He Q, Hu S. A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase. Medicine (Baltimore) 2021;100:e25581. [PMID: 33907107 DOI: 10.1097/MD.0000000000025581] [Reference Citation Analysis]
|
| 180 |
Grippo JF, Folitar I, Passe S, Jiang Q, Rodriguez I, Fettner SH, Calleja E. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers. Clin Transl Sci 2021;14:1524-34. [PMID: 33742764 DOI: 10.1111/cts.13016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 181 |
Maraolo AE. Choosing the appropriate pharmacotherapy for hepatitis B during pregnancy: what are the considerations? Expert Opin Pharmacother 2021;22:1083-6. [PMID: 33797300 DOI: 10.1080/14656566.2021.1909571] [Reference Citation Analysis]
|
| 182 |
Ullah H, Sajid M, Yan K, Feng J, He M, Shereen MA, Li Q, Xu T, Hao R, Guo D, Chen Y, Zhou L, Zhou L. Antiviral Activity of Interferon Alpha-Inducible Protein 27 Against Hepatitis B Virus Gene Expression and Replication. Front Microbiol 2021;12:656353. [PMID: 33868214 DOI: 10.3389/fmicb.2021.656353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 183 |
Takeuchi S, Tsuchiya A, Iwasawa T, Nojiri S, Watanabe T, Ogawa M, Yoshida T, Fujiki K, Koui Y, Kido T, Yoshioka Y, Fujita M, Kikuta J, Itoh T, Takamura M, Shirahige K, Ishii M, Ochiya T, Miyajima A, Terai S. Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis. NPJ Regen Med 2021;6:19. [PMID: 33785758 DOI: 10.1038/s41536-021-00132-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 184 |
Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, Wang Y. Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. J Clin Transl Hepatol 2021;9:143-8. [PMID: 34007795 DOI: 10.14218/JCTH.2020.00118] [Reference Citation Analysis]
|
| 185 |
Jeong H, Kim DH, Choi YM, Choi H, Kim D, Kim BJ. rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome. Microorganisms 2021;9:601. [PMID: 33803998 DOI: 10.3390/microorganisms9030601] [Reference Citation Analysis]
|
| 186 |
Tsuruoka M, Inoue J, Onishi Y, Ninomiya M, Kakazu E, Iwata T, Sano A, Sato K, Harigae H, Masamune A. Hepatitis B Virus Reactivation with Discontinuation of Nucleoside Analogue in Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation. Case Rep Gastroenterol 2021;15:178-87. [PMID: 33708067 DOI: 10.1159/000512397] [Reference Citation Analysis]
|
| 187 |
Liu C, Zheng Y, Li X, Li B, Wen L, Wang D, Feng Q, Jiang C. Study on the Expression Differences and the Correlation with H2BE Gene of Th Related Cytokines in SSDHS and LDSDS TCM-Syndromes of CHB Patients. Evid Based Complement Alternat Med 2021;2021:6291428. [PMID: 33688361 DOI: 10.1155/2021/6291428] [Reference Citation Analysis]
|
| 188 |
Li X, Liu X, Wang W. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases. Front Cell Dev Biol 2021;9:614847. [PMID: 33777929 DOI: 10.3389/fcell.2021.614847] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 189 |
Obeidat AE, Monti G, Sae-Ow W, Shinoda H, Lim H. Hepatitis E Virus Superinfection: an Underrecognized Trigger of Acute Hepatitis B Virus Flare. Cureus 2021;13:e13809. [PMID: 33859880 DOI: 10.7759/cureus.13809] [Reference Citation Analysis]
|
| 190 |
Luebbert CCE, Mansa R, Rahman R, Jakubek ZJ, Frahm GE, Zou S, Johnston MJW. Influence of bound dodecanoic acid on the reconstitution of albumin nanoparticles from a lyophilized state. Sci Rep 2021;11:4768. [PMID: 33637809 DOI: 10.1038/s41598-021-84131-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 191 |
Lim HC, Gordan JD. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS Comput Biol 2021;17:e1008699. [PMID: 33561166 DOI: 10.1371/journal.pcbi.1008699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 192 |
Huang W, Ji R, Ge S, Zhou D, Liu Z, Sun Y, Huang W, Lu C. MicroRNA-92b-3p promotes the progression of liver fibrosis by targeting CREB3L2 through the JAK/STAT signaling pathway. Pathol Res Pract 2021;219:153367. [PMID: 33618248 DOI: 10.1016/j.prp.2021.153367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 193 |
Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 194 |
He A, Wang W, Xia Y, Niu X. A Network Pharmacology Approach to Explore the Mechanisms of Artemisiae scopariae Herba for the Treatment of Chronic Hepatitis B. Evid Based Complement Alternat Med 2021;2021:6614039. [PMID: 33623529 DOI: 10.1155/2021/6614039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 195 |
Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 196 |
Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 197 |
Xun Z, Lin J, Yu Q, Liu C, Huang J, Shang H, Guo J, Ye Y, Wu W, Zeng Y, Wu S, Xu S, Chen T, Chen J, Ou Q. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8(+) T and NK cell function. Cell Mol Immunol 2021;18:461-71. [PMID: 33432062 DOI: 10.1038/s41423-020-00601-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 198 |
Yu Z, Ma X, Zhang W, Chang X, An L, Niu M, Chen Y, Sun C, Yang Y. Microarray Data Mining and Preliminary Bioinformatics Analysis of Hepatitis D Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2021;2021:1093702. [PMID: 33564675 DOI: 10.1155/2021/1093702] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 199 |
Khanam A, Ayithan N, Tang L, Poonia B, Kottilil S. IL-21-Deficient T Follicular Helper Cells Support B Cell Responses Through IL-27 in Patients With Chronic Hepatitis B. Front Immunol 2020;11:599648. [PMID: 33584666 DOI: 10.3389/fimmu.2020.599648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 200 |
Itokawa N, Atsukawa M, Tsubota A, Takaguchi K, Nakamuta M, Hiraoka A, Kato K, Abe H, Mikami S, Shimada N, Chuma M, Akito N, Uojima H, Ogawa C, Asano T, Tani J, Morishita A, Senoh T, Yamashita N, Oikawa T, Matsumoto Y, Koeda M, Yoshida Y, Tanabe T, Okubo T, Arai T, Hayama K, Iwashita AN, Kondo C, Tada T, Toyoda H, Kumada T, Iwakiri K. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B. JGH Open 2021;5:34-40. [PMID: 33490611 DOI: 10.1002/jgh3.12443] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 201 |
Xiao D, Wang J, Chen Z, Jin X, Xie Y, Yan D, Yang J. Restricted TcR β chain CDR3 clonotype is associated with resolved acute hepatitis B subjects. BMC Infect Dis 2021;21:111. [PMID: 33485302 DOI: 10.1186/s12879-021-05816-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 202 |
Volinsky I, Lombardo SD, Cheredman P. Stability Analysis and Cauchy Matrix of a Mathematical Model of Hepatitis B Virus with Control on Immune System near Neighborhood of Equilibrium Free Point. Symmetry 2021;13:166. [DOI: 10.3390/sym13020166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 203 |
Lei T, Tan F, Hou Z, Liu P, Zhao X, Liu H. Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib. Front Oncol 2020;10:596500. [PMID: 33552970 DOI: 10.3389/fonc.2020.596500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 204 |
Yoles I, Sheiner E, Abu-Freha N, Wainstock T. Maternal hepatitis B or C carrier status and long-term risk for offspring neurological morbidity: a population-based cohort study. J Dev Orig Health Dis 2021;:1-5. [PMID: 33472720 DOI: 10.1017/S2040174420001397] [Reference Citation Analysis]
|
| 205 |
Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 206 |
Le C, Sirajee R, Steenbergen R, Joyce MA, Addison WR, Tyrrell DL. In Vitro Infection with Hepatitis B Virus Using Differentiated Human Serum Culture of Huh7.5-NTCP Cells without Requiring Dimethyl Sulfoxide. Viruses 2021;13:97. [PMID: 33445753 DOI: 10.3390/v13010097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 207 |
Zeng QL, Yu ZJ, Ji F, Li GM, Zhang GF, Xu JH, Chen ZM, Cui GL, Li W, Zhang DW, Li J, Lv J, Li ZQ, Liang HX, Sun CY, Pan YJ, Liu YM, Wang FS. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clin Infect Dis 2021:ciaa1939. [PMID: 33395488 DOI: 10.1093/cid/ciaa1939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 208 |
Zhao Z, Tang Y, Wei Q, Zhang H. Establishment of A New HBV Cell Culture Model by Covalently Closed Circular DNA Direct Transfect. IOP Conf Ser : Earth Environ Sci 2021;632:032023. [DOI: 10.1088/1755-1315/632/3/032023] [Reference Citation Analysis]
|
| 209 |
Maheden K, Todd B, Gordon CJ, Tchesnokov EP, Götte M. Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. Enzymes 2021;49:315-54. [PMID: 34696837 DOI: 10.1016/bs.enz.2021.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 210 |
Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol 2021;56:158-67. [PMID: 33219410 DOI: 10.1007/s00535-020-01748-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 211 |
Ren Y, Shen L, Qian Z, Ling C, Zou Z, Liang R, Cao J, Han Q, Xu J. Increased Serum Sphingosine-1-Phosphate Accompanied with Secretion of Hepatitis B Surface Antigen. SSRN Journal. [DOI: 10.2139/ssrn.3863322] [Reference Citation Analysis]
|
| 212 |
de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 213 |
Watanabe Y, Tsuchiya A, Terai S. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clin Mol Hepatol 2021;27:70-80. [PMID: 33317249 DOI: 10.3350/cmh.2020.0194] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 214 |
Kaewdech A, Tangkijvanich P, Sripongpun P, Witeerungrot T, Jandee S, Tanaka Y, Piratvisuth T. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961-71. [PMID: 32668074 DOI: 10.1111/liv.14606] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 215 |
Yim HJ, Suh SJ, Jung YK, Hwang SG, Seo YS, Um SH, Lee SH, Kim YS, Jang JY, Kim IH, Kim HS, Kim JH, Lee YS, Yoon EL, Song MJ, Park JY. Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study. J Viral Hepat 2020;27:1306-18. [PMID: 32706461 DOI: 10.1111/jvh.13363] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 216 |
Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int 2020;14:958-72. [PMID: 33185803 DOI: 10.1007/s12072-020-10099-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 217 |
Suomalainen M, Prasad V, Kannan A, Greber UF. Cell-to-cell and genome-to-genome variability of adenovirus transcription tuned by the cell cycle. J Cell Sci 2020;134:jcs252544. [PMID: 32917739 DOI: 10.1242/jcs.252544] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 218 |
Jiang W, Wang L, Zhang Y, Li H. Circ-ATP5H Induces Hepatitis B Virus Replication and Expression by Regulating miR-138-5p/TNFAIP3 Axis. Cancer Manag Res 2020;12:11031-40. [PMID: 33173336 DOI: 10.2147/CMAR.S272983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 219 |
Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020;44:247-257. [PMID: 31559485 DOI: 10.1007/s00268-019-05197-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 220 |
Ribeiro CRA, Martinelli KG, de Mello VDM, Baptista BDS, Dias NST, Paiva IA, Lewis-Ximenez LL, Pinto LMO, de Paula VS. Cytokine, Genotype, and Viral Load Profile in the Acute and Chronic Hepatitis B. Viral Immunol 2020;33:620-7. [PMID: 33090087 DOI: 10.1089/vim.2020.0176] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 221 |
Paraskiv AL. Analysis of the chronic hepatitis B morbidity in conditions of mass vaccination in the Republic of Moldova. Medialʹ 2020. [DOI: 10.21145/2225-0026-2020-2-24-29] [Reference Citation Analysis]
|
| 222 |
Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis 2020;7:2049936120965027. [PMID: 33117536 DOI: 10.1177/2049936120965027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 223 |
Li W, Deng R, Liu S, Wang K, Sun J. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors. Liver Int 2020;40:2316-25. [PMID: 32666675 DOI: 10.1111/liv.14607] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 224 |
Shah SM, Rodin H, Pogemiller H, Magbagbeola O, Ssebambulidde K, Zewde A, Goers M, Katz B, Obaitan I, Abdo EF, Hassany SM, Elbadry M, Moussa AM, Mtengezo J, Dedzoe M, Henkle B, Bah MB, Sabongi M, Kayandabila J, Fell R, Ijeoma I, Ochola L, Yousif M, Debes JD. Hepatitis B Awareness and Vaccination Patterns among Healthcare Workers in Africa. Am J Trop Med Hyg 2020;103:2460-8. [PMID: 33025875 DOI: 10.4269/ajtmh.20-0521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 225 |
Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 226 |
Huang BX, Liu Y, Fan ZP, Si LL, Chen RJ, Wang J, Luo D, Wang FS, Xu DP, Liu XG. Investigation of immune escape-associated mutations of hepatitis B virus in patients harboring hepatitis B virus drug-resistance mutations. World J Gastroenterol 2020; 26(35): 5314-5327 [PMID: 32994690 DOI: 10.3748/wjg.v26.i35.5314] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 227 |
Lin Y, Zhao Z, Huang A, Lu M. Interplay between Cellular Autophagy and Hepatitis B Virus Replication: A Systematic Review. Cells 2020;9:E2101. [PMID: 32942717 DOI: 10.3390/cells9092101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 228 |
Su DN, Wu SP, Xu SZ. Mesenchymal stem cell-based Smad7 gene therapy for experimental liver cirrhosis. Stem Cell Res Ther 2020;11:395. [PMID: 32928296 DOI: 10.1186/s13287-020-01911-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 229 |
Lee H, Park Y, Choi Y. Overview of anti-Hepatitis B virus agents. jbv 2020;50:141-9. [DOI: 10.4167/jbv.2020.50.3.141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 230 |
Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 231 |
Ogawa M, Tsuchiya A, Watanabe T, Setsu T, Kimura N, Matsuda M, Hoshiyama Y, Saito H, Kanazawa T, Shiotani M, Sato T, Yagi T, Igarashi K, Yoshimura N, Takamura M, Aoyama H, Terai S. Screening and follow-up of chronic liver diseases with understanding their etiology in clinics and hospitals. JGH Open 2020;4:827-37. [PMID: 33102751 DOI: 10.1002/jgh3.12406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 232 |
Goto K, Nishitsuji H, Sugiyama M, Nishida N, Mizokami M, Shimotohno K. Orchestration of Intracellular Circuits by G Protein-Coupled Receptor 39 for Hepatitis B Virus Proliferation. Int J Mol Sci 2020;21:E5661. [PMID: 32784555 DOI: 10.3390/ijms21165661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 233 |
Wang W, Smith N, Makarov E, Sun Y, Gebhart CL, Ganesan M, Osna NA, Gendelman HE, Edagwa BJ, Poluektova LY. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine 2020;28:102185. [PMID: 32217146 DOI: 10.1016/j.nano.2020.102185] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 234 |
Jargalsaikhan G, Eichner M, Boldbaatar D, Bat-Ulzii P, Lkhagva-Ochir O, Oidovsambuu O, Dashtseren B, Namjil E, Genden Z, Yagaanbuyant D, Tuya A, Gurjav N, Mordorj A, Bungert A, Dashdorj N, Dashdorj N. Sensitivity and specificity of commercially available rapid diagnostic tests for viral hepatitis B and C screening in serum samples. PLoS One 2020;15:e0235036. [PMID: 32667957 DOI: 10.1371/journal.pone.0235036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 235 |
Abutaleb A, Khatun M, Clement J, Baidya A, Singh P, Datta S, Ahammed SM, George K, Mukherjee P, Santra A, Neogi S, Parikh S, Pillai V, Kottilil S, Chowdhury A. A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India. Hepatology 2021;73:1261-74. [PMID: 32659859 DOI: 10.1002/hep.31461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 236 |
Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 237 |
Zhang J, Liu X, Zhou W, Cheng G, Wu J, Guo S, Jia S, Liu Y, Li B, Zhang X, Wang M. A bioinformatics investigation into molecular mechanism of Yinzhihuang granules for treating hepatitis B by network pharmacology and molecular docking verification. Sci Rep 2020;10:11448. [PMID: 32651427 DOI: 10.1038/s41598-020-68224-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 238 |
Gholizadeh P, Safari R, Marofi P, Zeinalzadeh E, Pagliano P, Ganbarov K, Esposito S, Khodadadi E, Yousefi M, Samadi Kafil H. Alteration of Liver Biomarkers in Patients with SARS-CoV-2 (COVID-19). J Inflamm Res 2020;13:285-92. [PMID: 32669866 DOI: 10.2147/JIR.S257078] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 239 |
Yi TT, Zhang HY, Liang H, Gong GZ, Cai Y. Betaine-assisted recombinase polymerase assay for rapid hepatitis B virus detection. Biotechnol Appl Biochem 2021;68:469-75. [PMID: 32388885 DOI: 10.1002/bab.1940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 240 |
Wang K, Huang G, Chen Y, Wang Y. Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment. Med Sci Monit 2020;26:e921487. [PMID: 32587233 DOI: 10.12659/MSM.921487] [Reference Citation Analysis]
|
| 241 |
Koç DÖ, Özhan Y, Acar ET, Bireroğlu N, Aslan F, Keğin M, Sipahi H. Serum Neopterin Levels and IDO Activity as Possible Markers for Presence and Progression of Hepatitis B. Pteridines 2020;31:91-9. [DOI: 10.1515/pteridines-2020-0010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 242 |
Zhou QH, Wu FT, Pang LT, Zhang TB, Chen Z. Role of γδT cells in liver diseases and its relationship with intestinal microbiota. World J Gastroenterol 2020; 26(20): 2559-2569 [PMID: 32523311 DOI: 10.3748/wjg.v26.i20.2559] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 243 |
Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020;180:104824. [PMID: 32450266 DOI: 10.1016/j.antiviral.2020.104824] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 15.3] [Reference Citation Analysis]
|
| 244 |
Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 245 |
Li J, Le AK, Chaung KT, Henry L, Hoang JK, Cheung R, Nguyen MH. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int 2020;40:1052-61. [PMID: 32086988 DOI: 10.1111/liv.14415] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 246 |
Cho WR, Hung CH, Chen CH, Lin CC, Wang CC, Liu YW, Wu YJ, Yong CC, Chen KD, Tsai YC, Hu TH, Tsai MC. Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery. Sci Rep 2020;10:7290. [PMID: 32350365 DOI: 10.1038/s41598-020-64354-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 247 |
Mohammadzadeh I, Qujeq D, Yousefi T, Ferns GA, Maniati M, Vaghari-Tabari M. CRISPR/Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity. IUBMB Life. 2020;72:1603-1621. [PMID: 32344465 DOI: 10.1002/iub.2296] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 248 |
Liu Z, Wang J, Yuan H, Liu L, Bu Y, Zhao M, Yang G, Feng J, Liu Y, Li J, He Q, Zhang X. IFN-α2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx/MSL2/cccDNA/HBV/HBx in liver. Biochem Biophys Res Commun 2020;527:76-82. [PMID: 32446394 DOI: 10.1016/j.bbrc.2020.04.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 249 |
Jia X, Mo Z, Zhao Q, Bao T, Xu W, Gao Z, Peng L, Zhu X. Transcriptome alterations in HepG2 cells induced by shRNA knockdown and overexpression of TMEM2 gene. Biosci Biotechnol Biochem 2020;84:1576-84. [PMID: 32326855 DOI: 10.1080/09168451.2020.1756733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 250 |
Xiao W, Zhou Y, Yu P, Yang A, Zheng S, Tang H, Xie X. Prognostic value of chronic hepatitis B virus infection in patients with breast cancer in a hepatitis B virus endemic area. Ann Transl Med 2020;8:180. [PMID: 32309327 DOI: 10.21037/atm.2020.01.97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 251 |
Kammarabutr J, Mahalapbutr P, Okumura H, Wolschann P, Rungrotmongkol T. Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase. J Biomol Struct Dyn 2021;39:2502-11. [PMID: 32308149 DOI: 10.1080/07391102.2020.1751715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 252 |
Farooq PD, Sherman KE. Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV. Curr HIV/AIDS Rep 2019;16:395-403. [PMID: 31468298 DOI: 10.1007/s11904-019-00461-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 253 |
Liu Y, Le C, Tyrrell DL, Le XC, Li XF. Aptamer Binding Assay for the E Antigen of Hepatitis B Using Modified Aptamers with G-Quadruplex Structures. Anal Chem 2020;92:6495-501. [PMID: 32250595 DOI: 10.1021/acs.analchem.9b05740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 254 |
Inbar T, Sobeh Khalil S, Ram R, Ganzel C, Ofran Y. Low risk for viral reactivation during induction for acute myeloid leukemia in patients with resolved hepatitis B infection. Leukemia & Lymphoma 2020;61:1260-1262. [DOI: 10.1080/10428194.2019.1702187] [Reference Citation Analysis]
|
| 255 |
Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer 2020;19:77. [PMID: 32295598 DOI: 10.1186/s12943-020-01188-4] [Cited by in Crossref: 207] [Cited by in F6Publishing: 213] [Article Influence: 69.0] [Reference Citation Analysis]
|
| 256 |
Hao Q, Wang Z, Wang Q, Xia W, Cao H, Lu Z, Qian H. Differential expression profile of long noncoding RNAs in chronic HBV infection: New insights into pathogenesis. Journal of Medical Virology 2020;92:3390-3402. [DOI: 10.1002/jmv.25851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 257 |
Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, Tangkijvanich P. Reverse transcriptase droplet digital PCR vs reverse transcriptase quantitative real-time PCR for serum HBV RNA quantification. J Med Virol 2020. [PMID: 32219874 DOI: 10.1002/jmv.25792] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 258 |
Parvez MK, Al-Dosari MS, Arbab AH, Al-Rehaily AJ, Abdelwahid MAS. Bioassay-guided isolation of anti-hepatitis B virus flavonoid myricetin-3-O-rhamnoside along with quercetin from Guiera senegalensis leaves. Saudi Pharm J 2020;28:550-9. [PMID: 32435135 DOI: 10.1016/j.jsps.2020.03.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 259 |
Wang W, Zhou X, Bian Y, Wang S, Chai Q, Guo Z, Wang Z, Zhu P, Peng H, Yan X, Li W, Fu YX, Zhu M. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. Nat Nanotechnol. 2020;15:406-416. [PMID: 32123380 DOI: 10.1038/s41565-020-0648-y] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 26.0] [Reference Citation Analysis]
|
| 260 |
Morishita A, Fujita K, Iwama H, Chiyo T, Fujihara S, Oura K, Tadokoro T, Mimura S, Nomura T, Tani J, Yoneyama H, Kobayashi K, Kamada H, Guan Y, Nishiyama A, Okano K, Suzuki Y, Himoto T, Shimotohno K, Masaki T. Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol 2020;318:G401-9. [PMID: 31905024 DOI: 10.1152/ajpgi.00269.2019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 261 |
Asadi-Pooya AA, Bartolini L. Prevention and treatment of temporal lobe epilepsy: lessons from hepatitis B story! Int J Neurosci 2020;130:1151-5. [PMID: 32053411 DOI: 10.1080/00207454.2020.1730370] [Reference Citation Analysis]
|
| 262 |
Suomalainen M, Prasad V, Kannan A, Greber UF. Cell-to-cell and genome-to-genome variability of Adenovirus transcription tuned by the cell cycle.. [DOI: 10.1101/2020.02.27.967471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 263 |
Ciccullo A, Baldin G, Borghetti A, Di Giambenedetto S. Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Rev Anti Infect Ther 2020;18:279-92. [PMID: 32067525 DOI: 10.1080/14787210.2020.1729742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 264 |
Guo X, Chen D, Cai Q, Huang Z, Xu W, Peng L, Chen P. Minicircle DNA vector expressing interferon-lambda-3 inhibits hepatitis B virus replication and expression in hepatocyte-derived cell line. BMC Mol Cell Biol. 2020;21:6. [PMID: 32070272 DOI: 10.1186/s12860-020-00250-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 265 |
Meng Z, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:3127. [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 266 |
Lu S, Yang X, Jiang T, Zhou H, Wang W, Lin N, Zeng S, Ma Z, Jiang H. Pregnancy Impacts Entecavir Pharmacokinetics but Does Not Alter Its Renal Excretion. J Pharm Sci 2020;109:1811-8. [PMID: 32027922 DOI: 10.1016/j.xphs.2020.01.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 267 |
Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, Zhou J, Shi G, Fang N, Fan J, Cai J, Fan J, Lan F. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection.. [DOI: 10.1101/2020.02.03.931766] [Cited by in Crossref: 447] [Cited by in F6Publishing: 1] [Article Influence: 149.0] [Reference Citation Analysis]
|
| 268 |
Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 269 |
Peng S, Chen H, Li X, Du Y, Gan Y. Maternal age and educational level modify the association between chronic hepatitis B infection and preterm labor. BMC Pregnancy Childbirth 2020;20:38. [PMID: 31937269 DOI: 10.1186/s12884-020-2729-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 270 |
Fahmy NM, Al-Sayed E, Moghannem S, Azam F, El-Shazly M, Singab AN. Breaking Down the Barriers to a Natural Antiviral Agent: Antiviral Activity and Molecular Docking of Erythrina speciosa Extract, Fractions, and the Major Compound. Chem Biodivers 2020;17:e1900511. [PMID: 31800173 DOI: 10.1002/cbdv.201900511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 271 |
Wang Y, Zhang J, Jin Y, Xiao X, Zhang Q. Kushenin combined with entecavir for chronic hepatitis B: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e18898. [PMID: 32000393 DOI: 10.1097/MD.0000000000018898] [Reference Citation Analysis]
|
| 272 |
Tang L, Kottilil S, Wilson E. Strategies to eliminate HBV infection: an update. Future Virology 2020;15:35-51. [DOI: 10.2217/fvl-2019-0133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 273 |
Dagli O. Alkol ve uyuşturucu madde bağımlıları tedavi merkezinde hepatit ve HIV enfeksiyonlarının taranması. Pamukkale Medical Journal 2020. [DOI: 10.31362/patd.644886] [Reference Citation Analysis]
|
| 274 |
Zhang C, Yang Z, Wang Z, Dou X, Sheng Q, Li Y, Han C, Ding Y. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int J Med Sci 2020;17:383-9. [PMID: 32132873 DOI: 10.7150/ijms.39775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 275 |
Xun Z, Liu C, Yu QQ, Lin JP, Huang JL, Yang TW, Wu WN, Wu SH, Ou QS. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients. Clin Chim Acta 2020;502:120-7. [PMID: 31891671 DOI: 10.1016/j.cca.2019.12.020] [Reference Citation Analysis]
|
| 276 |
Li Y, Chen X, Huang H, Li G, Liao L, Yuan T, Deng S. Identification Of Novel lncRNAs For Detection Of HBV-Associated Hepatocellular Carcinoma. Onco Targets Ther 2019;12:10199-211. [PMID: 31819509 DOI: 10.2147/OTT.S230377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 277 |
Pyrski M, Mieloch AA, Plewiński A, Basińska-Barczak A, Gryciuk A, Bociąg P, Murias M, Rybka JD, Pniewski T. Parenteral-Oral Immunization with Plant-Derived HBcAg as a Potential Therapeutic Vaccine against Chronic Hepatitis B. Vaccines (Basel) 2019;7:E211. [PMID: 31835350 DOI: 10.3390/vaccines7040211] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 278 |
Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, Tangkijvanich P. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2019;26:1481-8. [PMID: 31446638 DOI: 10.1111/jvh.13195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 279 |
Sinn DH, Kim SE, Kim BK, Kim JH, Choi MS. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepat 2019;26:1465-72. [PMID: 31332935 DOI: 10.1111/jvh.13185] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 280 |
Chang L, Wang L, Ling N, Peng H, Chen M. Increase in liver γδ T cells with concurrent augmentation of IFN-β production during the early stages of a mouse model of acute experimental hepatitis B virus infection. Exp Ther Med 2020;19:67-78. [PMID: 31853274 DOI: 10.3892/etm.2019.8197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 281 |
Chung S, Roh EY, Park B, Lee Y, Shin S, Yoon JH, Song EY. GWAS identifying HLA-DPB1 gene variants associated with responsiveness to hepatitis B virus vaccination in Koreans: Independent association of HLA-DPB1*04:02 possessing rs1042169 G - rs9277355 C - rs9277356 A. J Viral Hepat 2019;26:1318-29. [PMID: 31243853 DOI: 10.1111/jvh.13168] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 282 |
Wang T, Chen W, Xu G, Zhang B, Wei S, Hu J, Zhang K. A universal strategy designed for selecting bench-to-bedside aptamers to serum and validated in hepatocellular carcinoma diagnosis. Microchemical Journal 2019;150:104152. [DOI: 10.1016/j.microc.2019.104152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 283 |
Yoles I, Sheiner E, Abu-Freha N, Wainstock T. Maternal hepatitis B or C status and the long-term risk of gastrointestinal morbidity for offspring: A population-based cohort study. Liver Int 2019;39:2046-51. [PMID: 31319010 DOI: 10.1111/liv.14193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 284 |
Wang F, Shen F, Wang Y, Li Z, Chen J, Yuan Z. Residues Asn118 and Glu119 of hepatitis B virus X protein are critical for HBx-mediated inhibition of RIG-I-MAVS signaling. Virology 2020;539:92-103. [PMID: 31706164 DOI: 10.1016/j.virol.2019.10.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 285 |
Yarovinsky TO, Mason SW, Menon M, Krady MM, Haslip M, Madina BR, Ma X, Moshkani S, Chiale C, Pal AC, Almassian B, Rose JK, Robek MD, Nakaar V. Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B. iScience 2019;21:391-402. [PMID: 31704650 DOI: 10.1016/j.isci.2019.10.040] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 286 |
Pesavento PA, Jackson K, Hampson TSTTB, Munday JS, Barrs VR, Beatty JA. A Novel Hepadnavirus is Associated with Chronic Hepatitis and Hepatocellular Carcinoma in Cats. Viruses 2019;11:E969. [PMID: 31640283 DOI: 10.3390/v11100969] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 287 |
Masand VH, El-sayed NNE, Rastija V, Rathore MM, Karnaš M. Identification of prodigious and under-privileged structural features for RG7834 analogs as Hepatitis B virus expression inhibitor. Med Chem Res 2019;28:2270-8. [DOI: 10.1007/s00044-019-02455-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 288 |
Shiina M, Yamada N, Sugiyama R, Murayama A, Aly HH, Muramatsu M, Wakita T, Imawari M, Kato T. Hepatitis B Virus Genotype-Dependent Vulnerability of Infected Cells to Immune Reaction in the Early Phase of Infection. Front Microbiol 2019;10:2427. [PMID: 31681253 DOI: 10.3389/fmicb.2019.02427] [Reference Citation Analysis]
|
| 289 |
Wang Y, Cao J, Zhang S, Sun L, Nan Y, Yao H, Fan J, Zhu LY, Yu L. MicroRNA-802 induces hepatitis B virus replication and replication through regulating SMARCE1 expression in hepatocellular carcinoma. Cell Death Dis 2019;10:783. [PMID: 31611549 DOI: 10.1038/s41419-019-1999-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 290 |
Arefkhah N, Vafazadeh S, Shahriarirad S, Ghorbani F, Zoghi S, Emami M, Zamiri B, Cheraghi MR, Sarvari J, Sarkari B. Serum levels of anti-hepatitis B surface antibodies among vaccinated children aged 1 to 12 years in a rural community in Fars Province, southern Iran. J Immunoassay Immunochem 2020;41:20-7. [PMID: 31590597 DOI: 10.1080/15321819.2019.1675696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 291 |
Zheng S, Liu L, Lu J, Zhang X, Shen H, Zhang H, Xue Y, Lin L. Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study. Medicine (Baltimore) 2019;98:e17590. [PMID: 31626130 DOI: 10.1097/MD.0000000000017590] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 292 |
Ning Q, Wu D, Wang GQ, Ren H, Gao ZL, Hu P, Han MF, Wang Y, Zhang WH, Lu FM, Wang FS. Roadmap to functional cure of chronic hepatitis B: An expert consensus. J Viral Hepat 2019;26:1146-55. [PMID: 31087479 DOI: 10.1111/jvh.13126] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 293 |
Liu S, Xin Y. HBV cccDNA: The Stumbling Block for Treatment of HBV Infection. J Clin Transl Hepatol 2019;7:195-6. [PMID: 31608210 DOI: 10.14218/JCTH.2019.00047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 294 |
Onitsuka K, Tokuda R, Kuwata-Higashi N, Kumamoto H, Aoki M, Amano M, Kohgo S, Das D, Haraguchi K, Mitsuya H, Imoto S. Synthesis and evaluation of the anti-hepatitis B virus activity of 4'-Azido-thymidine analogs and 4'-Azido-2'-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent. Nucleosides Nucleotides Nucleic Acids 2020;39:518-29. [PMID: 31514570 DOI: 10.1080/15257770.2019.1664749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 295 |
Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, Terai S. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration. Inflamm Regen. 2019;39:18. [PMID: 31516638 DOI: 10.1186/s41232-019-0107-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 296 |
Kong LN, He S, Li L, Lei QS, Wang T, Yao Y. Factors for self-management activities among rural patients with chronic hepatitis B: A cross-sectional study. J Clin Nurs 2019;28:3949-56. [PMID: 31408559 DOI: 10.1111/jocn.15037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 297 |
Arikan A, Sayan M, Sanlidag T, Suer K, Akcali S, Guvenir M. Evaluation of the pol/S Gene Overlapping Mutations in Chronic Hepatitis B Patients in Northern Cyprus. Pol J Microbiol 2019;68:317-22. [PMID: 31880877 DOI: 10.33073/pjm-2019-034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 298 |
Wei MT, Nguyen MH, Cheung R. Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection. Curr Hepatology Rep 2019;18:322-330. [DOI: 10.1007/s11901-019-00481-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 299 |
Chang XJ, Sun C, Chen Y, Li XD, Yu ZJ, Dong Z, Bai WL, Wang XD, Li ZQ, Chen D, Du WJ, Liao H, Jiang QY, Sun LJ, Li YY, Zhang CH, Xu DP, Chen YP, Li Q, Yang YP. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World J Gastroenterol 2019; 25(32): 4764-4778 [PMID: 31528100 DOI: 10.3748/wjg.v25.i32.4764] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 300 |
Li T, Mbala-Kingebeni P, Naccache SN, Thézé J, Bouquet J, Federman S, Somasekar S, Yu G, Sanchez-San Martin C, Achari A, Schneider BS, Rimoin AW, Rambaut A, Nsio J, Mulembakani P, Ahuka-Mundeke S, Kapetshi J, Pybus OG, Muyembe-Tamfum JJ, Chiu CY. Metagenomic Next-Generation Sequencing of the 2014 Ebola Virus Disease Outbreak in the Democratic Republic of the Congo. J Clin Microbiol 2019;57:e00827-19. [PMID: 31315955 DOI: 10.1128/JCM.00827-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 301 |
Pasternak G, Greenman J, Ieropoulos I. Removal of Hepatitis B virus surface HBsAg and core HBcAg antigens using microbial fuel cells producing electricity from human urine. Sci Rep 2019;9:11787. [PMID: 31409853 DOI: 10.1038/s41598-019-48128-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 302 |
Tsai WC, Hsu WT, Liu WD, Sun HY, Chuang YC, Huang YS, Cheng A, Lin KY, Huang YC, Chen GJ, Huang SH, Sheng WH, Hsieh SM, Hung CC, Chang SC. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection. Liver Int 2019;39:1408-17. [PMID: 30712284 DOI: 10.1111/liv.14059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 303 |
Manne V, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surg Nutr 2019;8:361-9. [PMID: 31489305 DOI: 10.21037/hbsn.2019.02.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 304 |
Zhu A, Liao X, Li S, Zhao H, Chen L, Xu M, Duan X. HBV cccDNA and Its Potential as a Therapeutic Target. J Clin Transl Hepatol 2019;7:258-62. [PMID: 31608218 DOI: 10.14218/JCTH.2018.00054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 305 |
Ma Z, Lu S, Sun D, Bai M, Jiang T, Lin N, Zhou H, Zeng S, Jiang H. Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy. Br J Pharmacol 2019;176:3236-49. [PMID: 31166004 DOI: 10.1111/bph.14756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 306 |
Lu JC, Zeng HY, Sun QM, Meng QN, Huang XY, Zhang PF, Yang X, Peng R, Gao C, Wei CY, Shen YH, Cai JB, Dong RZ, Shi YH, Sun HC, Shi YG, Zhou J, Fan J, Ke AW, Yang LX, Shi GM. Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics 2019;9:4678-87. [PMID: 31367249 DOI: 10.7150/thno.36276] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
|
| 307 |
Li Q, Huang C, Xu W, Hu Q, Chen L. A simple algorithm for non-invasive diagnosis of significant liver histological changes in patients with CHB and normal or mildly elevated alanine transaminase levels. Medicine (Baltimore) 2019;98:e16429. [PMID: 31305465 DOI: 10.1097/MD.0000000000016429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 308 |
Lin Y, Wu C, Wang X, Liu S, Zhao K, Kemper T, Yu H, Li M, Zhang J, Chen M, Zhu Y, Chen X, Lu M. Glucosamine promotes hepatitis B virus replication through its dual effects in suppressing autophagic degradation and inhibiting MTORC1 signaling. Autophagy. 2020;16:548-561. [PMID: 31204557 DOI: 10.1080/15548627.2019.1632104] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 309 |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
|
| 310 |
Huang YS, Sun HY, Chang SY, Chuang YC, Cheng A, Huang SH, Huang YC, Chen GJ, Lin KY, Su YC, Liu WC, Hung CC. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection. Hepatol Int 2019;13:431-9. [PMID: 31177505 DOI: 10.1007/s12072-019-09953-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 311 |
Prasidthrathsint K, Stapleton JT. Laboratory Diagnosis and Monitoring of Viral Hepatitis. Gastroenterol Clin North Am 2019;48:259-79. [PMID: 31046974 DOI: 10.1016/j.gtc.2019.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 312 |
Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 2019;19:511. [PMID: 31142283 DOI: 10.1186/s12885-019-5735-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 313 |
Chuaypen N, Tuyapala N, Pinjaroen N, Payungporn S, Tangkijvanich P. Association of NTCP polymorphisms with clinical outcome of hepatitis B infection in Thai individuals. BMC Med Genet 2019;20:87. [PMID: 31117968 DOI: 10.1186/s12881-019-0823-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 314 |
Chen Y, Wang Y, Chen Y, Yu Z, Chi X, Hu KQ, Li Q, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chi W, Dong Z, Wang X, Li Z, Xiao H, Chen D, Bai W, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Sun H, Deng M, Qi X, Zhang Z, Qi X, Yang Y. A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. Clin Transl Gastroenterol 2019;10:1-12. [PMID: 31033506 DOI: 10.14309/ctg.0000000000000033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 315 |
Ding X, Lei Q, Li T, Li L, Qin B. Hepatitis B core antigen can regulate NLRP3 inflammasome pathway in HepG2 cells. J Med Virol 2019;91:1528-36. [PMID: 31017673 DOI: 10.1002/jmv.25490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 316 |
Yu Q, Xiang L, Chen Z, Liu X, Ou H, Zhou J, Yang D. MALAT1 functions as a competing endogenous RNA to regulate SMAD5 expression by acting as a sponge for miR-142-3p in hepatocellular carcinoma. Cell Biosci 2019;9:39. [PMID: 31168355 DOI: 10.1186/s13578-019-0299-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 317 |
Yang L, Liu F, Tong X, Hoffmann D, Zuo J, Lu M. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infect Dis 2019;5:713-24. [PMID: 30896149 DOI: 10.1021/acsinfecdis.8b00337] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 318 |
Thi EP, Dhillon AP, Ardzinski A, Bidirici-Ertekin L, Cobarrubias KD, Cuconati A, Kondratowicz AS, Kwak K, Li AHL, Miller A, Pasetka C, Pei L, Phelps JR, Snead NM, Wang X, Ye X, Sofia MJ, Lee ACH. ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection. ACS Infect Dis 2019;5:725-37. [PMID: 30403127 DOI: 10.1021/acsinfecdis.8b00191] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 319 |
Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Seimiya T, Suzuki T, Tanaka E, Ishibashi R, Funato K, Koike K. Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus. Hepatology 2019;69:1903-15. [PMID: 30586159 DOI: 10.1002/hep.30491] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 320 |
Mok CC. Hepatitis B and C infection in patients undergoing biologic and targeted therapies for rheumatic diseases. Best Pract Res Clin Rheumatol 2018;32:767-80. [PMID: 31427054 DOI: 10.1016/j.berh.2019.03.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 321 |
Huang X, Zhang H, Qu C, Liu Y, Bian C, Xu Y. Depression and Insomnia Are Closely Associated with Thyroid Hormone Levels in Chronic Hepatitis B. Med Sci Monit 2019;25:2672-8. [PMID: 30973843 DOI: 10.12659/MSM.914444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 322 |
Zhang S. HLA Class II Allele Polymorphisms and the Clinical Outcomes of HBV Infection. Human Leukocyte Antigen (HLA) 2019. [DOI: 10.5772/intechopen.81366] [Reference Citation Analysis]
|
| 323 |
Iida-Ueno A, Enomoto M, Kozuka R, Tamori A, Kawada N. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial. J Med Virol 2019;91:1295-300. [PMID: 30815880 DOI: 10.1002/jmv.25442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 324 |
Shen XX, Qiu FZ, Shen LP, Yan TF, Zhao MC, Qi JJ, Chen C, Zhao L, Wang L, Feng ZS, Ma XJ. A rapid and sensitive recombinase aided amplification assay to detect hepatitis B virus without DNA extraction. BMC Infect Dis 2019;19:229. [PMID: 30836947 DOI: 10.1186/s12879-019-3814-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 325 |
van Halewijn GJ, Geurtsvankessel CH, Klaasse J, van Oord GW, de Knegt RJ, van Campenhout MJ, Boonstra A, van der Eijk AA. Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. J Clin Virol 2019;114:1-5. [PMID: 30852396 DOI: 10.1016/j.jcv.2019.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 326 |
Hasegawa K, Nishikawa H, Enomoto H, Iwata Y, Sakai Y, Ikeda N, Takashima T, Aizawa N, Takata R, Yoh K, Ishii N, Yuri Y, Nishimura T, Iijima H, Hatano E, Fujimoto J, Nishiguchi S. Proposed model for the prediction of intrahepatic covalently closed circular DNA level in patients with chronic hepatitis B. Hepatol Res 2019;49:271-83. [PMID: 30358027 DOI: 10.1111/hepr.13280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 327 |
Song LT, Liu RR, Zhai HL, Meng YJ, Zhu M. Molecular mechanisms of tetrahydropyrrolo[1,2-c]pyrimidines as HBV capsid assembly inhibitors. Archives of Biochemistry and Biophysics 2019;663:1-10. [DOI: 10.1016/j.abb.2018.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 328 |
Liu L, Liu Y, Chen R, Li X, Luo D, Zhao Y, Li Q, Huang B, Wang FS, Liu X, Xu D. Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. Antiviral Res. 2019;164:131-138. [PMID: 30796932 DOI: 10.1016/j.antiviral.2019.02.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 329 |
Luo H, Zhang XX, Cao LH, Tan N, Kang Q, Xi HL, Yu M, Xu XY. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients. World J Gastroenterol 2019; 25(6): 719-728 [PMID: 30783375 DOI: 10.3748/wjg.v25.i6.719] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 330 |
Lin Y, Wu C, Wang X, Liu S, Kemper T, Li F, Squire A, Zhu Y, Zhang J, Chen X, Lu M. Synaptosomal‐associated protein 29 is required for the autophagic degradation of hepatitis B virus. FASEB j 2019;33:6023-34. [DOI: 10.1096/fj.201801995rr] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 331 |
Al Mahtab M, Mf Akbar S, Begum M, Islam MA, Rahim MA, M Noor-E-Alam S, Alam MA, A Khondaker F, L Moben A, Mohsena M, Khan MSI, Huq MZ, Munshi S, Hoque A, Haque SA. Stem Cell Therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country. Euroasian J Hepatogastroenterol 2018;8:121-5. [PMID: 30828553 DOI: 10.5005/jp-journals-10018-1277] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 332 |
Choi YM, Lee SY, Kim BJ. Naturally Occurring Hepatitis B Virus Mutations Leading to Endoplasmic Reticulum Stress and Their Contribution to the Progression of Hepatocellular Carcinoma. Int J Mol Sci. 2019;20. [PMID: 30704071 DOI: 10.3390/ijms20030597] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 333 |
References. Addiction Medicine for Health Care Professionals 2019. [DOI: 10.1016/b978-0-323-68017-2.16001-6] [Reference Citation Analysis]
|
| 334 |
Hu J, Wang H, Hu Q, Cheng Y. G-quadruplex-based antiviral hydrogels by direct gelation of clinical drugs. Mater Chem Front 2019;3:1323-7. [DOI: 10.1039/c9qm00209j] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 335 |
Sheng N, Zou B, Tong H, Lu Y, Xing S, Song Q, Zhou G. Sequence-encoded quantitative invader assay enables highly sensitive hepatitis B virus DNA quantification in a single tube without the use of a calibration curve. Analyst 2019;144:5775-84. [DOI: 10.1039/c9an00970a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 336 |
Xia Y, Liang TJ. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology 2019;156:311-24. [PMID: 30243618 DOI: 10.1053/j.gastro.2018.07.057] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 16.3] [Reference Citation Analysis]
|
| 337 |
Kataoka H, Mochizuki T, Akihisa T, Kawasoe K, Kawachi K, Makabe S, Sawada A, Manabe S, Sato M, Amemiya N, Mitobe M, Akanuma T, Ito Y, Inoue T, Suzuki T, Matsui K, Moriyama T, Horita S, Ohara M, Honda K, Nitta K. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report. Medicine (Baltimore) 2019;98:e14014. [PMID: 30633192 DOI: 10.1097/MD.0000000000014014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 338 |
Guo L, Wang D, Ouyang X, Tang N, Chen X, Zhang Y, Zhu H, Li X. Recent Advances in HBV Reactivation Research. Biomed Res Int. 2018;2018:2931402. [PMID: 30687740 DOI: 10.1155/2018/2931402] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 339 |
Yarovinsky TO, Mason SW, Menon M, Krady MM, Haslip M, Madina BR, Ma X, Moshkani S, Chiale C, Pal AC, Almassian B, Rose JK, Robek MD, Nakaar V. Virus-like vesicles expressing multiple antigens for immunotherapy of chronic hepatitis B.. [DOI: 10.1101/491985] [Reference Citation Analysis]
|
| 340 |
Cagno V, Tintori C, Civra A, Cavalli R, Tiberi M, Botta L, Brai A, Poli G, Tapparel C, Lembo D, Botta M. Novel broad spectrum virucidal molecules against enveloped viruses. PLoS One 2018;13:e0208333. [PMID: 30532192 DOI: 10.1371/journal.pone.0208333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 341 |
Luo J, Chen S, Wang J, Ou S, Zhang W, Liu Y, Qin Z, Xu J, Lu Q, Mo C, Li S, Qin X. Genetic polymorphisms in complement receptor 1 gene and its association with HBV-related liver disease: A case-control study. Gene 2019;688:107-18. [PMID: 30529247 DOI: 10.1016/j.gene.2018.11.082] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 342 |
Xie G, Cui Z, Peng K, Zhou X, Xia Q, Xu D. Aidi Injection, a Traditional Chinese Medicine Injection, Could Be Used as an Adjuvant Drug to Improve Quality of Life of Cancer Patients Receiving Chemotherapy: A Propensity Score Matching Analysis. Integr Cancer Ther 2019;18:1534735418810799. [PMID: 30482065 DOI: 10.1177/1534735418810799] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 343 |
Liu H, Hou J, Zhang X. Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection? Virol Sin 2018;33:459-61. [PMID: 30374825 DOI: 10.1007/s12250-018-0062-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 344 |
Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, Ishibashi R, Seimiya T, Tanaka E, Koike K. Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction. Cell Mol Gastroenterol Hepatol 2019;7:297-312. [PMID: 30704981 DOI: 10.1016/j.jcmgh.2018.10.010] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 12.8] [Reference Citation Analysis]
|
| 345 |
Geethangili M, Ding ST. A Review of the Phytochemistry and Pharmacology of Phyllanthus urinaria L. Front Pharmacol 2018;9:1109. [PMID: 30327602 DOI: 10.3389/fphar.2018.01109] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 346 |
Tang L, Kottilil S. Treatment of Chronic Hepatitis B Infection-Reply. JAMA 2018;320:1202. [PMID: 30422297 DOI: 10.1001/jama.2018.10021] [Reference Citation Analysis]
|
| 347 |
Zhou YH. Treatment of Chronic Hepatitis B Infection. JAMA 2018;320:1201. [PMID: 30422294 DOI: 10.1001/jama.2018.10007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 348 |
. Incorrect Expansion of a Term and Other Clarifications. JAMA 2018;320:1202. [PMID: 30422281 DOI: 10.1001/jama.2018.9637] [Reference Citation Analysis]
|
| 349 |
Chen S, Zhang CZ, Liu L, Lu S, Pan Y, Wang C, He Y, Lin C, Yang X, Xie D, Yun J. A GYS2/p53 negative feedback loop restricts tumor growth in HBV-related hepatocellular carcinoma.. [DOI: 10.1101/373761] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 350 |
Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. Front Microbiol 2018;9:1611. [PMID: 30072974 DOI: 10.3389/fmicb.2018.01611] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 351 |
Verkhovsky E, Division of Gastroenterology, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI, USA, Naylor P, Benjaram S, Das Kundumadam S, Ehrinpreis M, Mutchnick M. Racial disparity in chronic hepatitis B infection in a predominately African American urban clinic population. AIMS Medical Science 2018;5:378-385. [DOI: 10.3934/medsci.2018.4.378] [Reference Citation Analysis]
|
| 352 |
[DOI: 10.1101/2020.02.03.931766] [Cited by in Crossref: 409] [Cited by in F6Publishing: 413] [Reference Citation Analysis]
|
| 353 |
[DOI: 10.1101/2020.02.03.931766] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
